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CHAPTER I 
 
 
INTRODUCTION 
 
Parkinson's disease (PD) is a chronic, degenerative neurological disorder that 
affects one in 100 people over age 60 (Lang and Lozano, 1998).  PD is progressive with a 
mean age at onset of 55, with an incidence that increases with age (Dauer and 
Przedborski, 2003).  There is still no objective test, or biomarker, for Parkinson's, so the 
rate of misdiagnosis can be relatively high.  Recent research indicates that at least one 
million people in the United States, and more than five million worldwide, have 
Parkinson's disease (Fahn, 2003). 
Parkinson's disease was first characterized by an English doctor, James Parkinson, 
in 1817 (Aronson 1986).  Today, we understand Parkinson to be a disorder of the central 
nervous system (CNS) that results from the loss of neuronal cells predominantly in the 
substantia nigra (SN) pars compacta (SNpc).  Because the SNpc cells produce dopamine, 
a chemical messenger responsible for coordination of movement, a loss of these neurons 
causes a fall in dopamine levels in the striatum, ultimately leaving patients less able to 
control their movement.  This leads to the “cardinal” symptoms of PD, such as resting 
tremor, bradykinesia, postural instability, and rigidity (Savitt et al., 2006).  Some of the
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“non-motor” symptoms include cognitive impairment, ranging from mild memory difficulties 
to dementia, and mood disorders, such as depression and anxiety  (Hoehn and Yahr, 1998).  
Also common are sleep difficulties, loss of sense of smell, speech and swallowing problems, 
unexplained pains, drooling, and constipation (Savica et al., 2010). 
The exact mechanism responsible for the neuronal loss in PD remains unclear; 
however, neuroinflammation appears to be involved (Hirsch et al., 1998; Hirsch et al., 2003; 
Hunot and Hirsch, 2003; McGeer et al., 2001; Whitton, 2007; Wyss-Coray and Mucke, 
2002).  Neuroinflammation seems to be instrumental given the increase in reactive glia and 
increased expression of inflammatory molecules in astroglia and microglia (Forno et al., 
1992; Miklossy et al., 2006).  Of these inflammatory molecules, the pro-inflammatory 
cytokines tumor necrosis factor – alpha (TNFα) and interleukin-1beta (IL-1β) are elevated in 
the striatum and cerebrospinal fluid (CSF) of PD patients.  Additionally, TNFα and IL-1β 
mediate cell death in a population of dopaminergic neurons and cause PD motor disabilities, 
possibly indicating an involvement of these cytokines in the pathology of the disease (De 
Lella Ezcurra et al., 2010; McGuire et al., 2001). 
In terms of cell types contributing to PD neuropathogenesis, microglia are shown to 
be involved (Cicchetti et al., 2002; Ghosh et al., 2007; McGeer and McGeer, 1998b).  For 
instance, analysis of PD patients by utilizing specific makers of activated microglia shows 
clear evidence of microglial activation in the SN (Cicchetti et al., 2002; Gerhard et al., 2006).  
Large numbers of human leukocyte antigen-DR (HLA-DR) and CD11b-positive microglia 
are found in the SN in the brains of these patients (McGeer et al., 1988).  Although past 
research has not thoroughly investigated the role of astrocytes in PD, increasing evidence 
points to astrocytes as contributors to dopaminergic neuronal degeneration (Henning et al., 
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2008; McGeer and McGeer, 2008; Yasuda et al., 2008).  Hence, a fuller characterization of 
astrocytes under PD-related conditions will enhance our understanding of PD-associated 
neuroinflammation.  This dissertation is an investigation of two PD-associated molecules, 
neuromelanin (NM) and α-synuclein, and their effect on human astroglial cells.  Reported 
first are the effects of NM and α-synuclein on neuroinflammatory molecules including 
chemokines (CXCL10) and inducible nitric oxide synthase (iNOS) in human astroglial cells.  
Given these inflammatory molecules are dependent upon the transcription factor, nuclear 
factor κB (NF-κB), the effects of NM and α-synuclein on NF-κB are also investigated.  The 
purpose of this study is to understand the actions of NM and α-synuclein on the modulation 
of pro-inflammatory signaling pathways in astroglial cells.  The rationale for examining the 
roles of NM and α-synuclein is to provide a foundation from which future research can 
investigate inflammatory-related therapeutic drugs for the treatment and prevention of PD-
associated neuroinflammation.  
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
2.1 Neuropathogenesis of Parkinson’s disease (PD) 
Parkinson’s disease affects the pigmented nigrostriatal dopaminergic neurons and 
results in a progressive neurodegeneration of these neurons.  PD is distinguished as the 
second most common neurodegenerative disorder after Alzheimer’s disease with a 
prevalence of 0.1% of the global population (Whitton, 2007).  The symptoms of PD 
typically appear when loss of at least 50% of the dopaminergic neurons in the SNpc 
occurs, leading to an over 80% reduction in dopamine levels in the striatum (Deumens et 
al., 2002; Lang and Lozano, 1998).  Depleted levels of dopamine, a neurotransmitter that 
dampens muscle jerkiness and exerts smooth muscle movement, causes unbalanced 
levels between dopamine and acetylcholine in the basal ganglia (Figure 1).  The 
imbalance of neurotransmitters ultimately prevents the basal ganglia from exerting 
controlled muscle contractions.  Uncontrolled movement will eventually lead to high 
muscle tension, and incidents of tremor and slow movement.  The clinical manifestations 
of PD include akinesia, bradykinesia, a rhythmic involuntary tremor at rest (‘pill rolling 
movement’), postural instability, and extrapyramidal rigidity in which major muscle 
groups become stiff.  
 Figure 1.  Pathway scheme of healthy state of brain versus Parkinson’s disease brain.
During movement, signals pass from the brain's cortex, via reticular formation and spinal cord 
(pathway A), to muscles, which contract. Other signals pass, by pathway B, to the basal ganglia; 
which dampen the signals in pathway A, reducing muscle tone so t
Dopamine is needed for this damping effect. Another transmitter, acetylcholine, inhibits the 
damping effect.  A lack of dopamine will reduce or abolish the damping
resulting in an increase in muscle tension and
http://www.holisticonline.com/remedies/parkinson/pd_brain.htm
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2.1.1 Neuroinflammation in PD 
While the exact mechanism by which PD causes neuropathology is not fully 
understood, new information has emerged in the past 15 years to strongly suggest that 
inflammation-derived oxidative stress (Hastings et al., 1996; Mizuno et al., 2008; 
Onyango, 2008), mitochondrial dysfunction (Mizuno et al., 2008; Onyango, 2008) and 
cytokine-dependent toxicity (Hirsch et al., 1998; Hirsch et al., 2003; Hunot and Hirsch, 
2003; McGeer et al., 2001; Whitton, 2007; Wyss-Coray and Mucke, 2002) may 
contribute to the neuronal degeneration and the progression of PD.  Numerous studies 
have implicated neuroinflammation in the pathogenesis of PD.  For example, men with 
high plasma concentrations of IL-6 have increased risk for PD (Chen et al., 2008).  
Several genetic studies have analyzed the relationship between polymorphism in 
neuroinflammation-associated genes and PD.  For instance, Wahner and colleagues 
(2007) found that the risk of PD is increased two-fold in patients with the homozygous 
variant of IL-1β at position -511 and TNFα at position -308 and that this risk is increased 
three-fold in carriers for both variants (Wahner et al., 2007).  Perhaps the most 
convincing evidence to support the claim that inflammation contributes to PD comes 
from epidemiological studies (Chen et al., 2003; McGeer and McGeer, 1998b).  A large 
study indicated that the incidence of PD in chronic users of non-aspirin non-steriodal 
anti-inflammatory drugs (NSAIDS), which scavenge free oxygen radicals and inhibit 
cyclo-oxygenase activity, was about 50% lower than that of age-matched non-users 
(Chen et al., 2003).  This suggests that inflammation may be a key player in PD. 
Neuroinflammation may also be evident in PD from studies of cellular and 
molecular examinations.  For instance, an increase in reactive glia and increase in 
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expression of inflammatory molecules in astroglia and microglia has been observed in the 
SN and striatum in PD patients (Forno et al., 1992; Miklossy et al., 2006) (Figure 2).   
 
Figure 2:  Inflammatory-related changes in Parkinson’s disease brains.  Cytokines found to 
be upregulated in the outlined regions (cerebral spinal fluid, substantia nigra, striatum) of the PD 
brain compared to control subjects.  Image adapted from Annals of Neurology with permission 
(Hunot and Hirsch, 2003) 
 
 
Parkinson’s disease is primarily a neurodegenerative disease; therefore, past research has 
thoroughly investigated the involvement of dopaminergic neurons as well as microglial 
cells.  To date, little research has been done to investigate the role of another type of CNS 
cell: the astrocytes. 
2.1.2 Role of astrocytes in normal vs PD brain 
Astrocytes are the major glial component of the CNS and constitute up to 50% of 
brain volume (Tower and Young, 1973).  Under physiological states, astrocytes support 
neurons, both physically as cellular matrix and physiologically by providing a stable 
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environment and growth factors (Anderson et al., 2003; Chen et al., 2006).  Astrocytes 
ensure neuronal homeostasis by taking up excess neurotransmitters and buffering the 
ionic content of the extracellular environment in the brain (Fields and Stevens-Graham, 
2002).  Additionally, astrocytes are known to play an important role in antioxidant 
defense in the brain (Morale et al., 2006).   
Astrocytic reactions also represent an important feature under pathophysiological 
conditions.  In addition to microglia, astrocytes have been shown to be involved in brain 
inflammation (Carpentier et al., 2005) in various neurodegenerative and neurological 
disorders (Tanuma et al., 2006; van Marle et al., 2004; Xia et al., 2000).  However, the 
role of astrocytes in the development of PD is still unclear.  In PD studies, astroglial 
activation, as measured by glial fibrillary acidic protein (GFAP) expression, has been 
reported in the SN and striatum of rodents exposed to drug-induced parkinsonism 
(Rodrigues et al., 2001).  Furthermore, a 30% increase in the density of astroglial cells in 
the SN of PD patients at post-mortem was detected by glutathione peroxidase-positive 
cell analysis (Damier et al., 1993).  Diseased brains of PD patients and cultured cells also 
illustrated astrocyte participation in the inflammatory response (Figure 3) by their 
production of noxious factors such as proinflammatory cytokines which damage CNS 
cells.  Specifically, inflammatory-changes in cytokine IL-1α/β, IL-6, IFNγ, TNFα, and 
chemokines monocyte chemotactic protein -1 (MCP-1), macrophage inflammatory 
protein -1α (MIP-1α), MIP-1β expression have been reported in PD patients as well as in 
PD animal models (Hirsch et al., 2003; Hunot and Hirsch, 2003; Kalkonde et al., 2007; 
Knott et al., 2000; McGeer and McGeer, 2008; Yasuda et al., 2008).  Therefore, astroglial 
cells are implicated in PD neuropathology, but further research is needed.  Given the 
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roles of astrocytes in the CNS, an impairment of astrocyte-neuron crosstalk may 
contribute to disease progression and impair the recovery process.  
Figure 3:  Representation of the hypothesized role of glial cells and inflammation in nerve 
cell death progression in Parkinson’s disease (PD).  In the brain of control subjects (left), 
resting glial cells surround healthy dopaminergic neurons.  After an initiating insult (the causative 
factors), some dopaminergic neurons degenerate by apoptosis and others are damaged or stressed 
(“diseased” dopaminergic neurons).  Through an unknown mechanism, these injured neurons 
trigger activation of glial cells, which is illustrated by morphological changes (blue arrows).  
Reactive glial cells secrete proinflammatory cytokines and inflammatory and/or immune-
associated markers (blue arrows).  In turn, this neuroinflammation can damage more 
dopaminergic neurons (red arrows), which will further activate the glial cells.  This vicious circle 
then could contribute to the propagation of nerve cell death and the development of parkinsonism 
(right).  Image copied from Annals of Neurology with permission (Hunot and Hirsch, 2003).  
 
2.2 The Tumor Necrosis Factor (TNF) family 
2.2.1 TNF cytokine family 
The Tumor Necrosis Factor (TNF) family is composed of 19 related cytokines 
that play a pivotal role in orchestrating innate inflammatory responses (Pfeffer, 2003).  
Following its isolation in 1975 and the cloning of its gene in 1984, studies showed two 
different TNFs in the family, TNFα and lymphotoxin (now known as TNFβ) (Aggarwal 
et al., 1984; Aggarwal et al., 1985b).  In 1985, a 30% amino acid similarity between the 
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two factors was found (Aggarwal et al., 1985b).  Additionally, the binding of TNFα to its 
receptor and its displacement by TNFβ confirmed the functional homology between the 
two proteins (Aggarwal et al., 1985a).  TNFβ is produced by lymphocytes, but in the 
CNS, TNFα is produced by astrocytes, microglia, and neuronal cells.  As summarized in 
Ernandez and Mayadas (2009), TNFα is synthesized as a propeptide with a long and 
atypical signal sequence, which is absent from the mature secreted cytokine.  A short 
hydrophobic stretch of amino acids serves to anchor the propeptide in lipid bilayers.  This 
26 kDa membrane-integrated protein (mTNFα) is released from the cell via proteolytic 
cleavage by TACE, the metalloprotease TNF-Alpha Converting Enzyme.  The soluble 17 
kDa protein (sTNFα) is secreted after cleavage of the propeptide.  In both the cell-
associated and secreted forms of TNFα, trimerization is required for biological activity.  
Both these forms are biologically active, and the cell-associated form is thought to be 
responsible for cell-to-cell contact (Kriegler et al., 1988).  The primary role of TNFα is in 
the regulation of immune cells.  Tumor necrosis factor α is able to induce apoptotic cell 
death and inflammation, and inhibit tumorigenesis and viral replication (Balkwill, 2009; 
Ernandez and Mayadas, 2009).   
2.2.2 TNFα receptors and CNS expression 
TNFα signals through two distinct cell-surface receptors: TNF receptor 1 
(TNFR1) and TNF receptor 2 (TNFR2) (Palladino et al., 2003).  Characterization of 
TNFR’s has been summarized by Palladino et al. (2003) as follows:  TNFR1 is the 
primary receptor for the soluble form of TNFα, whereas TNFR2 is the primary receptor 
for membrane-bound TNFα.  Similar to TNFα, both receptors have to form homotrimers 
to be biologically active.  Both receptors are transmembrane glycoproteins with multiple 
11 
 
cysteine-rich repeats in the extracellular N-terminal domains.  Although their 
extracellular domains share structural and functional homology, their intracellular 
domains are distinct, and transduce their signals through both overlapping and distinct 
pathways (Figure 4).  The main intracellular structural difference between TNFR1 and 
TNFR2 is the presence of the death domain (DD) in TNFR1, which is not present in 
TNFR2 (Palladino et al., 2003).  When TNFR1 is not activated, the DD is occupied by  
the SODD (silencer of DD protein), which prevents activation of the receptor in the 
absence of the ligand.  When TNFα binds to TNFR1, this induces the release of SODD 
and allows the TRADD (TNFR associated DD) to interact with the DD.  TRADD is an 
essential partner of TNFR1 for signal transduction.  TRADD can recruit the downstream 
adapter molecule FADD (fas-associated DD), which initiates the caspase pathway 
responsible for apoptotic cell death.  It can also interact directly with the TNF receptor-
associated factor 2 protein (TRAF2).  TRAF2 can then interact with RIP (receptor-
interacting protein) to mediate lymphocyte apoptosis.  TRAF2 can also trigger the 
activation of several inflammatory signaling pathways, including NF-κB, AP-1, c-Jun N-
terminal kinase stress kinases, and p38 mitogen-activated protein kinase (MAPK), which 
control TNF-induced gene expression (Ernandez and Mayadas, 2009; Palladino et al., 
2003). These inflammatory pathways are primarily activated by TNFR1.  Some of the 
proinflammatory properties of TNFα include induction of chemokines (monocyte-
chemoattractant protein-1, CXCL10 or IP10), cytokines (IL-1, IL-6), and other 
inflammatory mediators (reactive oxygen species, nitric oxide) (Tansey et al., 2007).  
Some reports indicate that TNFR1 mediates apoptosis and TNFR2 mediates proliferation; 
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thers suggest that the two TNFRs transduce their signals cooperatively (Mukhopadhyay 
et al., 2001; Weiss et al., 1998).   
 
 
Figure 4.  TNFα receptors and receptor-signaling pathways.  Diagram illustrating TNFR1 and 
TNFR2 and their role in signaling pathways.  The binding of membrane-bound or soluble TNFα 
induces the activation of TNFR2 and the release of SODD from TNFR1 to allow TRADD to 
interact with DD.  Downstream proteins and enzymes interact to allow signaling of TNFα 
receptors.  Activation of the TNFRs ultimately lead to cell apoptosis or inflammatory responses.  
SODD, silencer of death domain protein; TRADD, TNF receptor-associated death domain 
protein; TRAF2, TNF receptor-associated factor 2 protein; Etk/bmx, endothelial/epithelial 
tyrosine kinase; FADD, Fas-associated death domain protein; RIP, receptor interacting protein; 
JNK, c-Jun N-terminal kinase.  Image copied from Kidney International with permission 
(Ernandez and Mayadas, 2009).   
 
All nucleated cells express TNF receptors, although their distribution varies with 
cell type (Palladino et al., 2003).  TNFR1 is expressed constitutively on most cell types, 
13 
 
whereas expression of TNFR2 is highly regulated (Boka et al., 1994).  In the CNS, for 
example, TNFR1 is expressed on nigrostriatal dopaminergic neurons (Boka et al., 1994; 
McGuire et al., 2001; Mogi et al., 2000) as well as on astroglial cells (Fernandes et al., 
2006; Mennini et al., 2004; Sairanen et al., 2001; Yin et al., 2004).  TNFR2 is expressed 
primarily by immune cells including microglia (Dopp et al., 1997), but also reported in 
numerous other cell types including dopaminergic neurons (McGuire et al., 2001).   
2.2.3 Overview of TNFα’s role in PD 
TNFα is expressed at a minimal level in the CNS under basal conditions but 
becomes elevated after an insult, infection, or injury (Breder et al., 1993; Tansey et al., 
2007).  Dysregulation of TNFα production has been implicated in a variety of human 
diseases, such as Alzheimer’s disease (Fillit et al., 1991), multiple sclerosis (Hofman et 
al., 1989), human immunodeficiency virus (Grimaldi et al., 1991) as well as cancer 
(Bersani et al., 1986).  In PD, in particular, elevated TNFα and the contribution to 
dopaminergic neuronal dysfunction and cell death has been observed.  For example, 
TNFα is upregulated in the striatum and SN of post-mortem brains of PD patients (Boka 
et al., 1994; Mogi et al., 1994b) and increased in the serum and cerebrospinal fluid of PD 
patients compared to healthy individuals (Dobbs et al., 1999; Mogi et al., 1994b).  Also, 
in in vivo PD models TNFα is up-regulated in the striatum and SN (Mogi et al., 1999).  
Additionally, significantly elevated mRNA and protein levels of TNFα have been 
detected in the rodent midbrain SN within hours of in vivo administration of 
parkinsonism-inducing neurotoxins (Ferger et al., 2004; Mogi et al., 1999; Rousselet et 
al., 2002; Sriram et al., 2002).  Moreover, plasma TNFα levels remain elevated one year 
post administration of neurotoxin in non-human primates, showing its possible 
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involvement or influence in chronic inflammation (Barcia et al., 2005).  Importantly, 
TNFα was highly toxic to dopaminergic neurons in both in vitro (De Lella Ezcurra et al., 
2010; McGuire et al., 2001) and in vivo (Carvey et al., 2005) studies.  Furthermore, 
results from genetic evidence reveal that a single nucleotide polymorphism in the TNFα 
promoter is over-expressed, resulting in higher than normal TNFα production in a group 
of early onset PD patients (Nishimura et al., 2001).  Studies involving TNFα knockout 
and inhibitor proteins also support the role of TNFα in PD.  For example, MPTP-induced 
neurotoxicity was mitigated in mice lacking TNFα or both TNF receptors (Ferger et al., 
2004; Sriram et al., 2002). Chronic infusion of TNFα inhibitor proteins into rat SNpc 
displayed significant dopaminergic neuroprotective properties from parkinsonism-
inducing neurotoxin (McCoy et al., 2006).  Furthermore, glial cells in the SN of PD 
patients have enhanced TNFα production (Boka et al., 1994).  In principle, two 
mechanisms could account for TNFα’s neurotoxicity: either a direct mechanism through 
receptor binding on dopaminergic neuron or an indirect mechanism through glial-cell 
activation and expression of inflammatory factors.  Together, these studies utilizing 
histopathologic, epidemiologic, and pharmacologic analysis support the concept that 
TNFα is a critical mediator of dopamergic neurodegeneration in PD. 
 
2.3 The Interleukin (IL) -1 family 
2.3.1 IL-1 cytokine family 
The Interleukin (IL)-1 cytokine family is compromised of at least 11 ligands 
which play an important role in inflammation and host defense (Basu et al., 2004).  IL-1 
was first described in 1972 (Gery et al., 1972) and cloned in humans in 1985 (March et 
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al., 1985).  The cloning of IL-1 showed two separate genes encoding two different types 
of IL-1, IL-1α and IL-1β (Subramaniam et al., 2004).  These agonists display amino acid 
homology of 26% in humans (Dower et al., 1986).  Interleukin-1α and IL-1β are 
synthesized as large precursor proteins (31 kDa) by many cell types in the peripheral and 
central immune system, including monocytes, macrophages, neutrophils, hepatocytes, 
microglia, and astrocytes (Basu et al., 2004; Simi et al., 2007).  Pro-IL-1α is biologically 
active and cleaved by calpain to generate the mature 23 kDa protein.  Both forms of IL-
1α are biologically active and remain mostly intracellular, unless released following cell 
death (Allan et al., 2005).  In contrast, pro-IL-1β is biologically inactive and requires 
caspase-1 (also known as ICE, IL-1β converting enzyme) for cleavage into an active 17 
kDa protein, which is secreted out of the cell (Allan et al., 2005).  
The IL-1 family also has a third member that has been well characterized as a 
naturally occurring competitive IL-1 receptor antagonist, IL-1RA (Hannum et al., 1990).  
IL-1RA is produced by the same cells as IL-1 and is expressed as an intracellular isoform 
or a secreted isoform.  The secreted isoform of IL-1RA (22 kDa) is the only form 
reported in the brain (Hannum et al., 1990).  The receptor antagonist binds to the IL-1 
receptor with the same affinity as IL-1 but does not trigger signal transduction.  
Therefore, IL-1RA’s main function is to regulate the effects of IL-1 by blocking 
receptors.  Administration of IL-1RA in experimental animals resulted in neuroprotection 
following a number of insults including ischemia and excitotoxicity (Hagan et al., 1996; 
Yang et al., 1997).  
The biological activity of IL-1 is tightly controlled under physiolocial conditions.  
Upon stimulation, IL-1 is produced by a large variety of cells and acts in a 
16 
 
paracrine/autocrine fashion on target cells.  Roles of IL-1 include the regulation of 
metabolism, cytokine proteins, vascular system, and hematological molecules, with the 
primary role of IL-1 being a mediator of innate immunity with numerous CNS biological 
actions, including inflammation (Dinarello, 1988; Dinarello and Wolff, 1993; Dinarello, 
1996; Hallegua and Weisman, 2002).    
2.3.2 IL-1 Receptors and CNS expression 
The IL-1 family contains two forms of receptors (yielding ten receptor subtypes) 
that are from two different genes but display similarities in their transmembrane and 
extracellular domains (Martin and Falk, 1997).  The effects of IL-1α and IL-1β are 
mediated though actions on the type I IL-1 receptor, IL-1R1 (80 kDa), which exists in 
both membrane-bound and soluble forms (Subramaniam et al., 2004).  There is also a 
type II IL-1 receptor, IL-1R2 (60-65 kDa), but this receptor lacks an intracellular 
signaling domain so no downstream signaling is initiated when IL-1 binds.  Therefore, 
IL-1R2 is believed to act as a “decoy” receptor by preventing access of IL-1 to the 
functional IL-1R1 (Subramaniam et al., 2004).   
Signal transduction requires the binding of IL-1β to membrane-bound IL-1R1, 
which then associates with the membrane-bound IL-1 receptor accessory protein (IL-
1RAcP) (Rothwell and Luheshi, 2000).  The complex then recruits a number of 
intracellular adaptor molecules, including myeloid differentiation factor 88 (MyD88), IL-
1R-associated kinases (IRAK), and TNFR-associated factor 6 (TRAF6) to activate 
signaling via NF-κB, p38, p42/44, ERK1/2, and JNK MAPK (Figure 5), which will 
induce inflammatory-associated genes encoding chemokines (CCL2), growth factors 
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(nerve growth factor), adhesion molecules (matrix metalloproteinases) and cytokines (IL-
6, TNF) (Basu et al., 2004; John et al., 2005; Allan et al., 2005).   
 
 
Figure 5.  Actions of IL-1.  The IL-1 cytokine family members include two ligands (IL-1α and 
IL-1β), an antagonist (IL-1RA), and two receptors (IL-1R type 1 and IL-1R type 2).  The binding 
of IL-1α/β/ra to IL-1RI allows proteins and kinase to interact with the receptor and induce 
downstream signaling.  IL-1RII also binds IL-1, but lacks an intracellular domain and does not 
initiate signal transduction.  AcP, accessory protein; MAP, mitogen-activated protein; IRAK, 
interleukin-1 receptor associated kinase; TRAF, tumour necrosis factor receptor associated factor; 
NF-kB, nuclear factor-kB; JNK, c-jun amino terminal kinase  .Image copied from Trends in 
Neuroscience with permission (Rothwell and Luheshi, 2000) 
 
All members of the IL-1 family (IL-1α, IL-1β, IL-1R1, IL-1R2, and IL-1RA) 
have been observed in the CNS (Rothwell and Luheshi, 2000).  Interleukin -1α and IL-1β 
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are expressed at low levels in the healthy CNS, but are upregulated within minutes at the 
mRNA level and within hours at the protein level in response to neurotoxic stimuli (Allan 
et al., 2005; Simi et al., 2007).  Cellular sources of IL-1α and IL-1β and receptors IL-1R1 
and IL-R2 in the CNS appear to predominately be microglia and astrocytes (Davies et al., 
1999; Pearson et al., 1999) as well as neurons and oligodendroglia (Blasi et al., 1999).   
2.3.3 Overview of IL-1β in PD 
Interleukin-1β in particular has been implicated in a number of human diseases, 
including multiple sclerosis (McFarland and Martin, 2007), myasthenia gravis (Huang et 
al., 1998), epilepsy (Sheng et al., 1994), HIV-associated dementia (Zhao et al., 2001), 
Parkinson’s disease (Mogi et al., 1994a), and Alzheimer’s disease (Nicoll et al., 2000).  A 
significant increase in IL-1β within the striatum and SN of post-mortem patients as been 
observed (Hunot et al., 1999; Mogi et al., 1994a).  Similary, IL-1β is elevated in the CSF 
of PD patients compared to healthy patients (Blum-Degen et al., 1995).  Cell culture and 
animal studies also support an involvement of this pro-inflammatory cytokine in PD.  For 
instance, induction of chronic expression of IL-1β in adult rat SNpc using a recombinant 
adenovirus resulted in glial activation, progressive dopaminergic cell death, and akinesia 
(Ferrari et al., 2006).  In a separate study, midbrain dopaminergic neurons were treated 
with IL-1β which caused significant cell death, comparable to that induced by 6-OHDA 
(Long-Smith et al., 2009).  Although several studies are controversial regarding the 
neurotoxic role of IL-1β and suggest a more neuroprotective role (Nishimura et al., 2005; 
Saavedra et al., 2007), the most convincing evidence for IL-1β-induced 
neurodegeneration comes from genetic and pharmacological studies.  Genetic studies 
observed a significant increase in the microglial IL-1β genotype expression in patients 
19 
 
with PD compared to healthy patients (McGeer et al., 2002).  Furthermore, several 
studies found that the risk of PD doubled in carriers of the homozygous variant of IL-1β 
position -511 and TNFα position -308 and the risk was tripled for carriers of both variants 
(Nishimura et al., 2000; Wahner et al., 2007).  Pharmacological studies further illustrated 
that blockade of the IL-1R1 prevented the death of dopaminergic neurons induced by 
lipopolysachharide (LPS)-treated glial cells, suggesting that IL-1β produced from glial 
cells contributes to dopaminergic neuronal death (Koprich et al., 2008; Long-Smith et al., 
2010).  Inhibition of IL-1R1 not only attenuates neurodegeneration, but also reduces PD-
associated symptoms, such as dyskinesia, in an animal model (Barnum et al., 2008).  
Overall, evidence from several types of studies indicates that IL-1β plays a crucial role in 
the neurodegeneration of PD. 
 
2.4 The chemokine family: Overview 
Chemokines, which is short for ‘chemotactic cytokines’, are a family of small (8-
14 kDa) cytokines (Jin et al., 2008).  Characterization of chemokines have been 
summarized by Jin et al. (2008) as follows:  “The word ‘chemokine’ is derived from their 
ability to induce directed chemotaxis on cells that express the appropriate chemokine 
receptor along a chemical gradient of ligand—known as the chemokine gradient” (Jin et 
al., 2008).  Chemokines are classified into four highly conserved groups based on the 
position of the first two cysteines adjacent to the N-terminus—C (γ chemokines) CC (β 
chemokines), CXC (α chemokines), CX3C (δ chemokines).  In the human body, there are 
currently over 50 chemokines and at least 18 chemokine receptors that have been 
discovered (Ubogu et al., 2006).  Chemokine signaling plays a role in homeostasis, 
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development, and inflammation.  Homeostatic chemokines are chemokines that are 
produced and secreted without stimulation of the source cell (Luster, 1998; Sallusto et al., 
1997).  Chemokine secretion from lymph nodes for the chemoattraction of lymphocytes 
to screen for pathogen invasion is an example of homeostatic chemokines (Jin et al., 
2008).  Chemokines implicated in development are involved in several activities, 
including guiding progenitor cells to tissues for cellular maturation (Tiveron et al., 2006).  
Chemokines that contribute to inflammatory actions are released from a variety of cells in 
response to a number of agents (i.e., viruses, bacterial infection, pro-inflammatory 
cytokines).  Chemokines mainly function as chemoattractants for leukocytes and other 
cells from the blood to the site of infection or tissue damage (Jin et al., 2008).  In 
particular, a number of inflammatory chemokines also activate cells to initiate an immune 
response, an action that can lead to cellular survival or apoptosis (Zlotnik and Yoshie, 
2000). 
Receptors for chemokines are seven-transmembrane, G-protein-coupled receptors 
that are found on the surface of peripheral cells, such as leukocytes, as well as brain cells, 
including astrocytes, microglia, and neurons (Luster, 1998).  The actions of neuronal 
chemokine receptors upon binding by chemokines are known as contributors to 
neuropathogenesis, by inducing chemotaxis and intracellular calcium transients and 
amplifying neuronal dysfunction and death (Hirsch and Hunot, 2009; Shimoji et al., 
2009; Yasuda et al., 2008). 
2.4.1 Role of CXCL10/IP-10 in astrocytes and PD 
The gene of CXCL10, a 10 kDa α-chemokine, was first identified as an early 
response gene induced after interferon-γ exposure in a variety of cells, and was therefore 
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named interferon-inducible protein, IP-10 (Luster et al., 1985; Luster and Ravetch, 1987).  
CXCL10 is a chemoattractant for activated T cells, monocytes/macrophages (Taub et al., 
1993), microglia, and induces astrocyte proliferation (Flynn et al., 2003).  In the CNS, 
astrocytes are the major source of CXCL10 production (Oh et al., 1999).  Indeed, 
CXCL10 expression is significantly induced in TNFα-exposed human A172 astroglial 
cells (Davis et al., 2007).  Furthermore, CXCL10 mRNA and protein expression in 
astrocytes has been investigated and shown to be markedly increased in the CNS of HIV, 
AD, and MS subjects (Sui et al., 2004; Sui et al., 2006; Tanuma et al., 2006; Xia et al., 
2000).  For example, studies demonstrate through post-mortem analysis of neurologically 
challenged patients (i.e., MS and AD) that CXCL10 is up-regulated compared to healthy 
patients and the cellular source of this chemokine is astrocytes (Tanuma et al., 2006; Xia 
et al., 2000).  Tanuma and colleagues (2006) further state that astroglial-derived CXCL10 
may activate additional astrocytes through an autocrine or paracrine action since the 
CXCL10 receptor, CXCR3, is found on astrocytes.  Eventually, reactive gliosis occurs 
and is followed by microglia migration and activation, leading to degeneration of 
neuronal axons (Tanuma et al., 2006).  A relatively recent study has shown that CXCL10 
is up-regulated in the striatum of the PD in vivo MPTP model, yet the cellular source was 
not established (Kalkonde et al., 2007).  Furthermore, studies have indicated detrimental 
effects of CXCL10 on neuronal cells.  For instance, in a HIV study cultured human fetal 
brain neurons exposed to CXCL10 resulted in calcium dysregulation and activation of 
caspase-3 and ultimately apoptosis (Sui et al., 2004; Sui et al., 2006).  Consequently, 
strong support for the neurotoxic effects of CXCL10 exists in neurodegenerative 
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diseases, and thus, more research should be done exploring the modulation of CXCL10 in 
PD models and patients. 
 
2.5 The inducible nitric oxide synthase (iNOS) family 
2.5.1 The Role of iNOS 
Nitric oxide (NO) was first identified in 1980 as the endothelium-derived relaxing 
factor mediating relaxation of blood vessels (Furchgott and Zawadzki, 1980).  
Throughout years of research, NO became known as a highly diffusible, bioactive free 
radical with a short half-life (Steinert et al., 2010).  At low concentrations, NO is 
neuroprotective and mediates physiological signaling (vasodilation and 
neurotransmission), while at higher concentrations, it mediates immune and 
inflammatory actions and is neurotoxic (Liberatore et al., 1999).  NO is generated by 
nitric oxide synthase (NOS) via the enzymatic conversion of L-arginine to L-citrulline.  
There are three NOS genes with distinct tissue locations and functions– neuronal NOS 
(nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS).  The nNOS and eNOS are 
constitutively expressed and are calcium-dependent enzymes.  The inducible form, iNOS, 
does not require calcium for its activity and is expressed in various cell types including 
the astroglia and microglia (Steinert et al., 2010).  Inducible NOS expression in humans, 
however, appears to be in astrocytes rather than microglia (Steinert et al., 2010).  
Nevertheless, all three isoforms of NOS have been reported to contribute to 
neurodegenerative diseases (Maragakis and Rothstein, 2006).  This contribution is 
demonstrated by NOS production of NO, which reacts with the superoxide radical to 
ultimately produce reactive nitrogen species (RNS) – peroxynitrite and hydroxyl radical.  
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NO and its derivatives, RNS, target proteins, DNA, and lipids of cells, resulting in 
extensive cellular injury and ultimately cell death (Steinert et al., 2010).   
 
2.5.2 The importance of iNOS/NO in astrocytes and PD 
In the healthy human brain, astrocytes do not express iNOS; however, following 
trauma or an inflammatory insult, reactive astroglial cells have an up-regulated 
expression of iNOS (Galea et al., 1992).  In fact, the enhanced astroglial iNOS 
immunoreactivity has been reported in post-mortem brain tissue from patients with MS 
(Bo et al., 1994), AD (Wallace et al., 1997), and PD (Hunot et al., 1996).  Additionally, 
the iNOS product, NO, is suspected to contribute to a number of neurodegenerative 
diseases, especially PD (Arimoto and Bing, 2003; Hunot et al., 1996; Iravani et al., 2002; 
Liu et al., 2002; Okuno et al., 2005).  In a PD study, Liberatore et al. (1999) demonstrated 
a significant up-regulation of iNOS and gliosis after MPTP administration to mice.  This 
group of researchers further observed dopaminergic neurodegeneration following iNOS 
enhancement, whereas iNOS mutant mice were resistant to the effects of MPTP.  A 
previous study also revealed an astrocytic inflammatory response of an increase in iNOS 
and NO in an in vitro PD-associated gene DJ-1 model (Waak et al., 2009).  This increase 
in NO resulted in an increase of oxidative species which coincided with neuronal 
apoptosis (Waak et al., 2009).  Immunoreactivity analyses of the mesencephalon of post-
mortem PD patients further supported the importance of nitric oxide by illustrating a 
significant increase in glial iNOS levels, which may be neurotoxic to dopaminergic 
neuronal cells (Hunot et al., 1996).  Several other studies have also shown that 
administration of selective iNOS inhibitors protected nigrostriatal dopaminergic neurons 
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in a 6-OHDA model (Broom et al., 2011) and in a MPTP mouse model (Kim et al., 
2010).  Even motor performance in models of PD was affected negatively by NO and 
improved significantly by inhibition of NOS expression.  Padovan-Neto et al. (2009) 
illustrated this improvement in motor performance when L-DOPA-induced dyskinesia in 
a rodent model of PD was attenuated after rodents were administrated with NOS 
inhibitors (Padovan-Neto et al., 2009).  
 
2.6 The importance of NF-κB in glia 
The transcription factor nuclear factor – κB (NF-κB) was discovered about 25 
years ago and observed to bind to the enhancer of the immunoglobulin (Ig) κ light chain 
gene in B cells (Sen and Baltimore, 1986).  Nuclear factor – κB is a ubiquitously 
expressed transcription factor that compromises five members, p50, p52, p65 (Rel-A), c-
Rel, and Rel-B, which share a N-terminal Rel homology domain allowing dimerization, 
interaction with NF-κB inhibitor IκBα, and binding to DNA at κB sites of target genes 
(Ghosh and Karin, 2002).  Nuclear factor-κB proteins form homo- or hetero-dimers that 
remain inactive in the cytoplasm by interaction with IκBs (Ghosh and Karin, 2002).  IκBs 
are inhibitory molecules which mask the NF-κB nuclear localization sequence (Malek et 
al., 2001; Whiteside and Israel, 1997).  These molecules are evolutionarily conserved and 
composed of IκBα, IκBβ, IκBε, IκBγ, IκBζ, Bcl-3, p-105, and p-100 (Whiteside and 
Israel, 1997).  Depending on the stimulus, NF-κB activation can occur through either the 
classical pathway or the alternative pathway (Figure 6).  In the classical or canonical 
pathway, NF-κB signaling is stimulated by pro-inflammatory cytokines such as TNFα 
and IL-1β (Bonizzi and Karin, 2004).  This stimulation triggers the activation of the IκB 
kinase (IKK) complex, which is composed of IKKα, IKKβ, and IKKγ/NEMO (NF-κB 
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essential modulator).  IKKβ then phosphorylates IκB proteins on two serine residues, 
Serine 32 and 36, which then results in the ubiquitination and degradation of IκB by the 
26S proteasome (Ghosh and Karin, 2002).  The nuclear localization sequence of NF-κB 
proteins are then unmasked and the proteins are able to translocate to the nucleus and 
bind to κB sites in the promoter or enhancer regions of target genes and activate their 
transcription.  The alternative pathway or non-canonical pathway involves the upstream 
kinase NF-κB inducing kinase (NIK), which activates IKK complex, and leads to the 
phosphylation and processing of p100 to p52.  The release of p52-containing dimers then 
allows for nuclear translocation and DNA binding (Derudder et al., 2003; Xiao et al., 
2001).  This alternative pathway is thought to play a role in the expression of genes 
involved in the development and maintenance of secondary lymphoid organs and in 
adaptive immunity.  The pathway operates only upon stimulation by lymphotoxin β, B-
cell-activating-factor, or CD40 (Bonizzi and Karin, 2004).  However, it is the classical 
pathway that is involved in the control of innate immunity and inflammation (Baud and 
Karin, 2001; Bonizzi and Karin, 2004; Ghosh and Karin, 2002) and in the regulation of 
the production of several pro-inflammatory mediators including cytokines (TNFα), 
chemokines (monocyte chemotactic protein-1), enzymes (cyclooxygenase-2), and nitric 
oxide.  
Several reports suggest a critical role for NF-κB in the manifestation of PD (Aoki 
et al., 2009; Niranjan et al., 2010).  In support of the role of NF-κB in astrocytes in PD, 
studies have shown an enhancement of active NF-κB levels in astrocytes in the presence 
of PD-associated neurotoxin MPTP (Aoki et al., 2009; Niranjan et al., 2010).  Both 
groups of researchers demonstrate an increase in NF-κB translocation, with nuclear p65 
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levels significantly increased in astroglial cells after MPTP treatment.  A 70-fold increase 
in the nuclear translocation of NF-κB compared to age-matched healthy controls is also 
seen in substantia nigra dopaminergic neurons of post-mortem PD patients (Hunot et al., 
1997).  Therefore, these studies suggest a critical role for NF-κB, especially through the 
classical pathway, in PD. 
 
Figure 6. Classical and alternative pathways of NF-κB activation.   A model depicting the two 
signaling pathways to NF-κB.  (A) The classical pathway is mediated by IKKβ and leads to 
phosphorylation of IκB.  Inputs for the classical pathway include TNFR1/2, TCR and BCR, and 
TLR/IL-1R.  (B) The alternative pathway involves NIK activation of IKKα and leads to the 
phosphorylation and processing of p100, generating p52-RelB heterodimers.  Input signals for the 
alternative pathway include LTβR, BAFFR, and CD40R.  Image copied from Genes and 
Development with permission (Hayden and Ghosh, 2004). 
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2.6.1 The importance of NF-κB in CXCL10 production in astrocytes  
The signaling pathway responsible for the induction of CXCL10 is important to 
examine in the pathogenesis of neuronal diseases.  CXCL10 induction was found to be 
regulated transcriptionally by the activation of NF-κB (Williams et al., 2009b). 
Interestingly, the CXCL10 promoter NF-κB binding site has exclusive affinity to p50/p65 
heterodimers (Ohmori and Hamilton, 1995).   We have established, through the use of 
specific NF-κB inhibitors, a signaling pathway responsible for the production of CXCL10 
in astroglial is NF-κB (Davis et al., 2007).  In fact, the inactivation of astroglial NF-κB 
resulted in down-regulation of the production of CXCL10 expression, and ultimately led 
to a neuroprotective effect on retinal neurons following ischemic injury (Dvoriantchikova 
et al., 2009).  In another study, inactivation of NF-κB and reduced CXCL10 resulted in a 
faster recovery after spinal cord injury in transgenic mice compared to non-transgenic 
mice (Brambilla et al., 2005).  Furthermore, human astrocytes co-exposed to HIV-1 Tat 
and proinflammatory cytokines resulted in the induction of CXCL10 at both the RNA 
and protein level (Williams et al., 2009b).   
2.6.2 The importance of NF-κB in iNOS/NO induction in astrocytes and PD 
The involvement of NF-κB in the production of NO has been illustrated in several 
studies.  First, the human iNOS gene contains eight NF-κB binding sites (Taylor et al., 
1998).  Secondly, Davis and colleagues (2005) illustrated the dependency of iNOS 
expression in astroglial cells on NF-κB by the use of several NF-κB inhibitors (MG-132, 
helenalin, BAY 11-7082).  In an in vitro PD model, mesencephalic cells exposed to 
manganese demonstrated increased NO generation during the activation of NF-κB, which 
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was blocked by NF-κB inhibitor (SN50) (Prabhakaran et al., 2011).  Furthermore, in a PD 
animal model, administration of paraquat intraperitoneally resulted in the induction of 
nitric oxide and production of lipid peroxidation in the striatum (Gupta et al., 2010).  
However, this induction of iNOS mRNA and protein and expression of lipid peroxidation 
were significantly attenuated in the animal models by the NF-κB inhibitor pyrrolidine 
dithiocarbamate (Gupta et al., 2010).  A recent study explored the role of astroglial NF-
κB in iNOS induction and NOS2 expression in an in vivo and in vitro PD model, 
respectively (Miller et al., 2011).  This study by Miller et al. (2011) demonstrated that 
MPTP-exposed astrocytes had colocalized expression of iNOS and NF-κB, with an 
increased protein nitration in nigral dopaminergic neurons.  Inhibition of NF-κB in 
astroyctes by mutant IκBα suppressed expression of NOS2 and protected co-cultured 
neurons from astrocyte-mediated apoptosis (Miller et al., 2011).  Consequently, NF-κB 
has been implicated in the induction of iNOS in PD pathogenesis, yet further studies are 
required to examine the role of astroglial NF-κB on iNOS induction in PD.   
Astrocytes are the major source of NF-κB-induced CXCL10 and iNOS in the 
CNS (Ohmori and Hamilton, 1995; Taylor et al., 1998).  This chemokine and enzyme 
potentially exacerbate an inflammatory attack by mediating chemotaxis and producing 
reactive nitrogen species at the site of insult, respectively.  Therefore, studies should be 
done on astrocytes to elucidate the role of these inflammatory factors (NF-κB, CXCL10, 
iNOS) on Parkinson’s disease neuropathogenesis.   
2.7 Neuromelanin 
2.7.1 The role of NM in normal brain 
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In the human brain, the neurotransmitter dopamine (DA) has been implicated in a 
number of roles, including voluntary movement, reward, motivation, and mood 
(Bromberg-Martin et al., 2010).  Tyrosine hydroxylase (TH) produces L-3,4-
dihydroxyphenylalanine (DOPA), which is then rapidly converted to DA by aromatic 
amino acid decarboxylase (AADC) (Sidhu et al., 2004).  Cytosolic DA can have several 
destinations, including accumulation in synaptic vesicles via uptake by vesicular 
monoamine transporter 2 (VMAT2).  Dopamine can also be metabolized by monoamine 
oxidase (MAO) into 3,4-Dihydroxyphenylacetic acid (DOPAC).  Cytosolic DA can also 
be released from the cell via reverse transport through the dopamine transporter (DAT) 
(Sulzer, 2007; Zucca et al., 2004).  If these processes are insufficient to control the levels 
of cytosolic DA, excess cytosolic DA can be easily oxidized.  Dopamine oxidation can 
occur via two major pathways: auto-oxidized or enzymatic oxidation, both of which 
produce dopamine-quinones and ROS in the cytosol.  Oxidized dopamines (oxDA) are 
highly reactive and exert cytotoxicity in DA neurons and surrounding neural cells 
(Asanuma et al., 2003; Miyazaki and Asanuma, 2008).  Oxidized DA reacts with cysteine 
residues on proteins to form DA-Cys-protein products, which can be phagocytized in 
autophagic vacuoles and become double-membraned NM granules over time (Fedorow et 
al., 2005; Zucca et al., 2004).  Neuromelanin, meaning ‘black’ substance in neurons, is 
what causes the dark pigmentation of certain neurons and is found at its highest levels in 
the SNpc and the locus coeruleus (LC) (Graham, 1979; Zecca et al., 2004).  In the human 
brain, NM first appears in the SNpc around the third year of life (Fenichel and Bazelon, 
1968) and accumulates linearly with age, reaching concentrations of 2.3-3.7 µg/mg in the 
SNpc of healthy subjects aged 50-90 years old (Zecca et al., 2002).  
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It has been suggested that the synthesis of NM plays a protective role within the 
cell (Fedorow et al., 2005; Zecca et al., 2003; Zucca et al., 2004).  Neuromelanin prevents 
the accumulation of toxic cytosolic DA derivatives by incorporating them into the 
polymer (Sulzer et al., 2000).  Neuromelanin may also play a protective role by acting as 
a ‘black hole’ capable of chelating redox active metals (iron, zinc, copper), toxic metals 
(mercury and lead), and a wide variety of toxic compounds (MPP+) (D'Amato et al., 
1986; Enochs et al., 1994; Zecca et al., 2002), indicating that it could be a high capacity 
storage system that prevents neuronal damage.  
2.7.2 The role of NM in PD brain 
Although brain regions other than the pigmented SNpc are involved in the 
pathology of PD, the loss of NM-containing neuronal cells in this area represents a 
cardinal pathologic diagnostic criterion for the disease.  Specifically, NM levels in PD 
patients were 1.2-1.5 µg/mg in the SNpc, which are less than half of age-matched 
controls (Zecca et al., 2002).  In fact, analysis of PD midbrain shows that dopaminergic 
neurons of the SN containing NM are predominately more vulnerable to loss than the 
unpigmented neurons (Gibb, 1992; Kastner et al., 1992).  It has been suggested that the 
pigment itself increases the vulnerability of SN neurons and leads to neurodegeneration 
(Offen et al., 1997).  The observed decrease of NM in the SNpc of PD patients further 
supports the loss of the pigmented neurons during PD (Gibb and Lees, 1991; Pakkenberg 
et al., 1991).  Others have stated that the level of NM actually decreases in surviving 
neurons of the SN (Kastner et al., 1992; Mann and Yates, 1983) due to a reduced 
biosynthesis, increased degradation, higher vulnerability of heavily pigmented neurons, 
or a combination of these mechanisms.   
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In contrast to NM’s cytoprotective roles, there is also evidence of this polymer 
exhibiting a cytotoxic role and, hence, explaining the death of pigmented neuronal cells 
in PD brains. Studies have reported that when free neuronal iron increases and saturates 
the chelating sites of NM, NM could lead to an increased production of free radicals, 
such as hydrogen peroxide and hydroxyl radicals (Double et al., 2002; Zareba et al., 
1995).  As hydrogen peroxide and hydroxyl radicals degrade the integrity of NM, 
cytotoxic redox active metal ions will be released from NM and could accelerate SNpc 
neuronal death by exacerbating oxidative stress (Double et al., 2002; Enochs et al., 1994).  
The release of NM from these dying neurons could trigger a vicious cycle of 
neuroinflammation and neurodegeneration.  If the anti-oxidative defense mechanism is 
overwhelmed and the cumulative stress is severe enough, exacerbation of neuronal 
depletion could increase the onset or symptoms of PD (Tansey et al., 2007).  
2.7.2.1 The effect of NM on proinflammatory factors in PD 
In subjects with juvenile (Ishikawa and Takahashi, 1998), idiopathic, and MPTP-
induced parkinsonism (Langston et al., 1999), neuropathological examinations have 
demonstrated the presence of insoluble extracellular NM granules, which arise following 
SNpc cell death and remain in the EC space in large amounts for long periods of time 
(months, years).  In a patient with MPTP-induced parkinsonism, extraneuronal melanin 
was found with activated microglial cells and gliosis even 12 years after exposure to the 
neurotoxin (Langston et al., 1999).  An in vitro study demonstrated the effect of human 
NM on rat microglia and illustrated NM’s ability to trigger microgliosis, microglial 
chemotaxis, and microglial activation with subsequent release of proinflammatory and 
neurotoxic mediators such as NO, TNFα, and IL-6 (Wilms et al., 2003; Zhang et al., 
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2011).  Addition of NM to microglial cells also activated the NF-κB and p38 MAPK 
signaling pathways (Wilms et al., 2003).  Further support for glial activation by 
extraneuronal NM was shown in the SNpc of post-mortem patients of PD and MPTP-
intoxication, where NM deposits were found to be phagocytosed by microglia (Zucca et 
al., 2004) and to induce glia activation (Zhang et al., 2011).  Due to the lack of research 
on NM effects on astrocytes, the present study investigated the pro-inflammatory factors 
triggered by exogenous NM and its pathogenic mechanism in human astrocytoma cells.  
The findings from these studies may provide insights into the inflammatory mechanism 
of PD caused by the extraneuronal deposits of NM. 
2.8 Alpha-synuclein 
2.8.1 The role of α-synuclein in normal brain 
Alpha-synuclein belongs to the synuclein family along with β- and γ-synuclein 
(George, 2002; Ueda et al., 1993), which have been described only in vertebrates.  Alpha-
synuclein is predominately expressed in the brain neocortex, hippocampus, striatum, 
thalamus, and cerebellum and is the only synuclein known to be implicated in disease 
(Iwai et al., 1995).  Human α-synuclein is a small acidic protein (14 kDa) composed of 
140 amino acid residues and predominately localized in presynaptic terminals in the 
CNS, where it loosely associates with synaptic vesicles (Norris et al., 2004).  Alpha-
synuclein was first identified as the precursor of the non-Aβ component peptide, which is 
present in extracellular amyloid plaques of AD patients (Iwai et al., 1995; Ueda et al., 
1993).  Although the physiological roles of α-synuclein are not fully understood, 
numerous studies demonstrate the role of α-synuclein in DA neurotransmission 
regulation (Dev et al., 2003; Sidhu et al., 2004).  Studies demonstrate α-synuclein’s role 
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by its effect on neuronal plasticity (Clayton and George, 1998), regulation of neuronal 
membrane trafficking via vesicle budding or turnover (Chen et al., 1997), regulation of 
the size of synaptic vesicle pools in neurons (Murphy et al., 2000), inhibition of TH 
activity (Perez et al., 2002), and regulation of the number of plasma membrane DATs 
(Lee et al., 2001).   
2.8.2 The role of α-synuclein in PD brain 
The implication of α-synuclein’s role in the pathophysiological process of PD is 
still far from obvious; however, a prerequisite of α-synuclein neuropathy is its 
oligomerization into soluble protofibrils followed by their coalescence into insoluble 
fibrils, and accumulation into Lewy bodies (LB) (Lee and Lee, 2002; Maries et al., 2003).  
Several conditions induce α-synuclein aggregation, including α-synuclein mutations 
(A30P, A53T, E46K), over-expression, and exposure to neurotoxins (MPTP, rotenone) 
and oxidative factors (free iron, oxidized dopamine) (Dev et al., 2003; Lee, 2008).  Once 
aggregation is initiated, the bioavailability of α-synuclein is greatly diminished such that 
normal physiological functions regulated by α-synuclein may be severely compromised, 
which in turn, could further worsen the initial cellular insult (Sidhu et al., 2004) (see 
Figure 7).   
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Figure7. Overview of the consequences of α-synuclein aggregation that turn it from a 
neuroprotective to a toxic molecule.  Under physiological conditions (right side of diagram), α-
synuclein is able to lower TH activity by blocking interactions with 14-3-3 proteins and various 
kinases, which are required to trigger a high TH activity.  Alpha-synuclein also contributes to a 
normal rate of synaptic vesicle formation, which leads to an efficient clearance of cytoplasmic 
dopamine through VMAT2.  Normal amounts of soluble α-synuclein at the nerve terminals helps 
to hold the dopamine transporter (DAT) into a cytoplasmic compartment, preventing overload of 
extracellular dopamine into the neuronal cytoplasm.  Overall, α-synuclein tends to decrease the 
amount of free dopamine inside neurons, and its possible transformation into a reactive and 
highly toxic molecule.  In contrast, under pathological conditions (left side of the diagram), 
lowering the amount of soluble α-synuclein tends to increase free cytoplasmic dopamine and the 
formation of reactive oxygen species (ROS).  Formation of protofibrils or aggregates and LBs 
diminishes the availability of the physiological forms of α-synuclein, favoring an increase in TH 
and DAT, and diminishing vesicles formation and neuronal plasticity.  Image copied from The 
FASEB Journal with permission (Sidhu et al., 2004) 
35 
 
The link between α-synuclein and PD, including idiopathic PD, was solidified by the 
finding that fibrillar aggregates of this protein are the main components of the 
pathological hallmark of PD: LB and Lewy neurites (Spillantini et al., 1998).  It is widely 
accepted that during the course of PD, α-synuclein is not only accumulated in cytosolic 
space and vesicles, leading to a possible internal effect on SNpc neurons, but is also 
released into the extracellular space.  Furthermore, the presence of α-synuclein has been 
observed in the CSF and blood of Parkinson’s disease patients (El-Agnaf et al., 2003).  
The presence of α-synuclein in the extracellular space can thereby gain access to the glial 
environment.  More specifically, α-synuclein released from neurons induces glial 
activation, resulting in production of neurotoxic molecules (superoxide anions, 
intracellular reactive oxygen species, prostaglandin E2, intercellular adhesion molecule-
1, and IL-6) which lead to neuroinflammation and neurodegeneration of dopaminergic 
neurons (Kahle et al., 2000; Klegeris et al., 2006; Xu et al., 2002; Zhang et al., 2005; 
Zhou et al., 2002).  Because of this action, there has long been speculation that α-
synuclein underlies PD pathogenesis.   
2.8.2.1 The effect of α-synuclein on proinflammatory factors in PD 
Numerous in vitro and in vivo studies have been carried out to elucidate the 
neuroinflammatory and neurodegenerative effects of α-synuclein leading to neuronal 
dysfunction and death.  These effects are seen in experimental PD models using mutated, 
overly-expressed, and more recently, extracellular α-synuclein.  Studies examining the 
effects of overexpressed or mutated α-synuclein in cells and transgenic animals resulted 
in mitochondrial dysfunction, which led to formation of inclusion bodies, promotion of 
oxidative stress, and ultimately neuronal loss (Hsu et al., 2000; Kirik et al., 2002; Klein et 
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al., 2002; Masliah et al., 2000; Zhou et al., 2002).  Some transgenic models of 
overexpressed α-synuclein also demonstrated an increase in the production or expression 
of several proinflammatory molecules, including TNFα, IL-1β, NO, and CCR3 in 
microglia which then led to neurodegeneration when exposed to neurons (Gao et al., 
2008; Su et al., 2008a; Su et al., 2009).  Only a few studies have actually examined the 
effects of extracellular α-synuclein on glial cells.  For example, extracellular α-synuclein 
was shown to activate microglial cells and to up-regulate several pro-inflammatory 
molecules, such as NO, IL-1β, IL-6, COX-2, CX3CR1, NOS2, and NADPH oxidase with 
production of ROS (Su et al., 2008a; Su et al., 2009; Zhang et al., 2005).  The effect of α-
synuclein on microglial activation resulted in cytotoxicity of a human neuroblastoma cell 
line (El-Agnaf et al., 1998) and primary mesencephalic dopaminergic neuron-glial system 
(Zhang et al., 2005).  Klegeris et al. (2006) studied the effects of extracellular α-synuclein 
on human astroyctes and astrocytoma cells and demonstrated an induction of ICAM-1 
and IL-6 (Klegeris et al., 2006).  The current study describes the effect of exogenous α-
synuclein on pro-inflammatory factors CXCL10 and iNOS and the pathogenic 
mechanism in human astrocytoma cells.  These findings may provide insights into the 
inflammatory mechanism of PD caused by the abnormal accumulation of α-synuclein 
aggregates. 
2.9 Understanding the effects of PD-associated molecules in human astroglial 
cells 
In this dissertation, the cell-dependent effects of NM and α-synuclein are 
investigated through cellular and molecular characterizations.  Examining the expression 
of inflammatory factors by these PD-associated molecules will provide a better 
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understanding of the role of the molecules in PD.  Although numerous effectors such as 
environmental toxins and genetic factors can initiate SNpc and striatum neuronal damage, 
this introduction has described the release of NM and α-synuclein from neurons inducing 
the production and release of neurotoxic glial factors (Kahle et al., 2000; Klegeris et al., 
2006; Wilms et al., 2003; Xu et al., 2002; Zhang et al., 2005; Zhou et al., 2002).  These 
glial factors, in turn, provoke further neuronal death and further release of NM and α-
synuclein, thus leading to a vicious cycle of neuroinflammation and neurodegeneration.  
This process has recently been examined in rodent and human microglial cells, yet still 
remains to be explored in astroglial cells.  Therefore, it is important to elucidate the 
effects of NM and α-synuclein on human derived astroglial cells.   
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2.10 Hypothesis and Specific Aims 
The hypothesis for this dissertation is presented two-fold: 
1 - Neuromelanin and α-synuclein, separately, increase cytokine-induced NO and 
CXCL10 expression in A172 astroglial cells.  
The first hypothesis was examined through experiments within the following 
specific aims: 
a) Determine time and dose-dependent effects of NM and α-synuclein 
(separately) on NO and chemokine protein expression in TNFα/IL-1β-exposed 
astrocytes. 
b) Determine the role of NM and α-synuclein on iNOS and CXCL10 mRNA 
expression, respectively. 
c) Determine the effect of α-synuclein on CXCL10 mRNA stability. 
2 - NM and α-synuclein, separately, increase the effect of cytokine-induced NF-κB 
activation in A172 cells. 
The second hypothesis was examined through experiments within the following 
specific aims: 
a) Determine the role of NM and α-synuclein on NF-κB-DNA binding. 
b) Determine the effect of α-synuclein on I-κBα phosphorylation. 
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The goal of this study is to examine the human astroglial response under protein-
inflammation conditions with NM and α-synuclein.  Furthermore and most importantly, 
the mediators (iNOS, CXCL10, NF-κB) examined in this dissertation have been shown to 
play crucial roles in the process of inflammation and neuronal death.  Consequently, 
valuable information is gained by understanding the actions of NM and α-synuclein on 
the induction of neurotoxic molecules and the signaling pathway in a cytokine-exposed 
human astroglial condition.  This dissertation is the first study that examines the effects 
of NM and α-synuclein on human astroglial cells, ultimately advancing the development 
for therapeutic strategies to combat PD-associated neuroinflammation.  
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CHAPTER III 
 
 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 Cell cultures 
3.1.1 Human A172 Astrocytoma cells 
Human A172 cells (ATCC #CRL-1620) were maintained in Dulbecco's modified 
Eagle's medium (DMEM) containing 2 mM L-glutamine, 10% fetal bovine serum, 1% 
nonessential amino acids, 50 U/ml penicillin, 0.05 mg/ml streptomycin and 2 µg/ml 
amphotericin B.  Proinflammatory pathways in these human brain cells (ATCC #CRL-
1620; American Type Culture Collection, Manassas, VA) have been previously 
characterized (Davis et al., 2002; Davis and Syapin, 2004a; Davis and Syapin, 2004b) 
and used in various pharmacology- and neurochemistry-based studies (Guthikonda et al., 
1998; Kubota et al., 2001; Zaheer et al., 1995). 
3.1.2 Human SK-N-SH Neuronal cells 
The human SK-N-SH neuronal cells (ATCC #HTB-11) were maintained in RPMI 
1640 with 10% fetal bovine serum, 50 U/ml penicillin, 0.05 mg/ml streptomycin, and 2 
µg/ml amphotericin B as previously described (Wallace et al., 2006).  
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3.1.3 Human CHME-5 Microglial cells 
Human CHME-5 microglial cell line (developed by Dr. Marc Tardieu, Paris, 
France (Janabi et al., 1995) was a kind gift from Dr. Pierre Talbot, Quebec, Canada. 
CHME-5 cells were maintained in DMEM containing 10% fetal bovine serum, 2 mM L-
glutamine, 50 U/ml penicillin, 0.05 mg/ml streptomycin, and 2 µg/ml amphotericin B.  
All cultures were maintained in a humidified incubator at 37°C, 5% CO2 and 95% air 
with the culture medium changed every 48–72 hour. Experimental cultures were seeded 
at a cell density to provide 80–90% confluence at the time of treatment.  
3.2 Preparation of PD-associated molecules 
3.2.1 Oxidized DA Preparation 
Dopamine was dissolved in serum-free DMEM (containing iron) to obtain a 10 
mM solution followed by filter sterilization. One ml of solution was transferred to a 
microcentrifuge tube, covered with aluminum foil to avoid light exposure, and vortexed 
gently for 1 h.  Oxidized DA was then diluted in culture medium to the required 
concentration (3.7-600 µM). (Methodology obtained from Douglas Walker, PhD at Sun 
Health Research Institute in Sun City, Arizona) 
3.2.2  Neuromelanin Preparation 
Neuromelanin was isolated as previously described (Zecca et al., 2008) from 
substantia nigra samples obtained during autopsies of subjects who died without any 
known neurological or psychiatric disorders. The purity of the NM was assessed by 
elemental analysis, amino acid analysis and electron paramagnetic resonance 
spectroscopy as previously described (Zecca et al., 2000; Zecca et al., 2002). Stock NM 
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was resuspended in 0.5 ml ethanol, agitated gently, and ethanol was evaporated under 
nitrogen flow.  NM was then suspended in water (0.5 mg/ml).  The sample tube was 
wrapped in aluminum foil to avoid light exposure, sonicated for 10-20 minutes followed 
by gently agitation for 3-4 days at room temperature.  After the initial 15 hours of 
agitation, granules were broken up with a glass Pasteur pipette tip, sonicated for 10 
minutes, and returned to shaker.  For further fragmentation of granules during the 4 day 
shaking, sonication was done for 10 minutes every 15-20 hours.  Aliquots of 180 µl were 
stored at -80◦C in sterile 1.5ml centrifuge tubes.  Upon thawing, samples were sonicated 
for 20 minutes, followed by 24 hour of agitation to obtain a homogenous suspension.  
NM suspension was diluted to desired concentrations (0.02-15 µg/ml) in serum-free 
culture medium and incubated at room temperature for 2 hour before adding to cell 
cultures.  The biological relevance of this concentration range of NM was based on the in 
situ concentrations found in the substantia nigra of normal subjects (Zecca et al., 2001). 
3.2.3 Alpha-synuclein Preparation 
Purified human α-synuclein was obtained from r-Peptide (cat.# S-1001). Upon 
arrival, α-synuclein power was resuspended in 0.5 ml of sterile water to obtain a 
concentration of 1 mg/ml.  Aliquots of 10 µl were stored at -80oC in sterile 1.5 ml 
centrifuge tubes.  Upon thawing, samples were diluted with 900 µl of sterile PBS to 
obtain a stock concentration of 690 nM.  Tubes were agitated (“aged”) for either 7 or 14 
days at 37oC for formation of an inflammatory-inducing conformation, followed by 
dilution to desired concentrations in serum free medium and exposure to appropriate cell 
wells.  The concentration and duration of α-synuclein is provided in the results section of 
each experiment.   
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3.3 MTT test for cell viability 
To assess cell viability, the MTT assay was performed according to a modified 
version of a previously described procedure (Carmichael et al., 1987).  Cell viability in 
response to treatment was determined colorimetrically by measuring the reduction of 
tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yI)-2,5 diphenyl Tetrazolium Bromide, 
Table 1) to insoluble formazan by mitochondrial dehydrogenase.  Following the 
appropriate length of stimulation, culture media was replaced with fresh serum free 
medium containing 0.55 mg/ml MTT and returned to humidified incubator (37oC) for 45 
minutes.  Media was aspirated and cells will be dissolved in 1 ml dimethyl sulphoxide 
(DMSO, ACS grade Sigma D-8779) to dissolve the developed formazan for a minimum 
of ten minutes on a rocker at room temperature.  Absorbance was measured at 492 nm 
using a BIO-TEK HT spectrophotometer.  The absorbance values from wells containing 
drug treated cells were compared to the values from untreated control cells to determine 
the viability of cells in each treatment group. 
 
Table 1.  Preparation of MTT solution 
MTT stock 
solution 
Dissolve 100 mg MTT (Sigma M-5655) in 20 ml sterile PBS, Sterile 
filter in 50 ml centrifuge tube, Wrap with aluminum foil and store at 
4oC 
 
 
3.4 Analysis of iNOS expression 
As an index of iNOS induction, nitrite accumulation in the culture media was 
determined spectrophotometrically using the Griess reagent (Davis et al., 2002).  First, 
standard curve was prepared in the same media as used in experiments.  Quantitative 
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standards were generated by serial diluting sodium nitrite into culture medium.  To 
prepare standard curve (Table 2), one ml of medium was pipetted into test tubes labeled 
#1-6.  Two ml of medium was pipetted into tube #7.  The standard was pipetted into tube 
#7 at a volume of 16 µl and was mixed gently on vortex machine.  One ml from tube #7 
was transferred into tube #6 and gently mixed on vortex machine.  This transfer was 
repeated in 1:1 dilutions until tube #2 had 2ml.  Tube #1 did not contain the standard 
since it was used as the blank.  Therefore, the nitrite concentrations in 0.1 ml were: 
Tube #1 = 0 nmol 
Tube #2 = 0.25 nmol 
Tube #3 = 0.5 nmol 
Tube #4 = 1.0 nmol 
Tube #5 = 2 nmol 
Tube #6 = 4 nmol  
Tube #7 = 8 nmol 
Duplicate 0.1 ml aliquots from these tubes were pipeted into appropriate wells of a 96-
well Falcon plate (first two columns). After this, duplicate 0.1 ml aliquots from unknown 
samples were pipeted into appropriate wells of a 96-well Falcon plate.  The Griess 
reagent was prepared for addition to the wells containing standards and samples.  Eleven 
ml of Griess reagent was prepared for each 96-well plate (5.5 ml of Solution 1 + 5.5 ml of 
Solution 2, Table 2).  One hundred µl of the Griess reagent was added to each well and 
plate was read after 5 minutes.  Absorbance was read at 546 nm using a BIO-TEK HT 
spectrophotometer.  Total cell protein (see section 3.6.1) was calculated to normalize data 
as nanomoles of nitrite per milligram of protein.   
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Table 2.  Preparation of Nitrite assay standard and solutions 
Standard 10 mM sodium nitrite in distilled water (dissolve 0.069 g of sodium 
nitrite into 85 ml distilled water, bring up to 100 ml with water after 
resuspension) 
Solution 1 0.1% (W/V) naphthylethylenediamine dihydrochloride in distilled 
water (dissolve 0.5 g into 450 ml distilled water, bring up to 500 ml 
with water after resuspension) 
Solution 2 1% (W/V) sulfanilaminde in 5% (V/V) concentrated phosphoric acid 
(carefully add 25 ml concentrated phosphoric acid into 400 ml 
distilled water, dissolve 5 g sulfanilamide, bring up to 500 ml with 
water after resuspension) 
 
 
3.5  Quantitative analysis of mRNA expression 
3.5.1  RNA isolation  
Total RNA was isolated from astrocytic cells with TRIzol reagent (Invitrogen) 
using manufacturer’s instructions.  Briefly, cells were lysed directly in the culture dish by 
adding 700 µl of TRIzol and passing the cell lysate several times through a pipette.  The 
homogenized samples were transferred into eppendorf tubes (per one sample) and 
incubated for 5 minutes at room temperature (RT) to permit the complete dissociation of 
nucleoprotein complexes.  To separate RNA from DNA and protein, 200 µl of chlorform 
was added to each tube and shaken vigorously by hand for 15 seconds.  Samples were 
incubated for 2-3 minutes at RT, followed by centrifuged for 15 minutes at 12,000 × g 
(4oC).  Following centrifugation, the mixture separated into a lower red, phenol-
chloroform phase (protein), an interphase (DNA), and a colorless upper aqueous phase 
(RNA).  Since the RNA remains exclusively in the aqueous phase, the aqueous phase was 
transferred 100 µl at a time into a fresh eppendorf tube.  The RNA was precipitated by 
mixing with 700 µl (1:1 ratio of TRIzol and isopropyl alcohol) isopropyl alcohol.  
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Samples were incubated at RT for 10 minutes and centrifuged for 10 minutes at 12,000 × 
g for 10 minutes at 4oC.   The RNA precipitate was observed as a white pellet on the 
bottom of tubes.  The supernatant was removed and the RNA was washed twice to 
remove any residual compounds.  Supernatant was washed with 75% ethanol (1 ml/tube), 
and tubes were vortexed and centrifuged at 7,400 × g for 5 minutes at 4oC.  These last set 
of steps were repeated once more.  At the end of this procedure, the RNA pellet was dried 
at RT for 5 minutes to remove remaining ethanol.  RNA samples were dissolved in 30 µl 
RNase-free water and incubated for 10 minutes at 55-60oC in water bath.  The tubes were 
vortexed and centrifuged.  RNA samples were quantitated on a ND-1000 (NanoDrop 
Technologies) and their integrity was determined by denaturing agarose gel 
electrophoresis.  To evaluate the quantity and purity of the extracted RNA, 
spectrophotometric readings were obtained at wavelengths of 260 nm and 280 nm. A 
reading at wavelength of 260 nm allowed for calculation of the concentration of RNA in 
the sample. An optical density of 1 corresponded to approximately 40 µg/ml of single-
stranded RNA. The ratio of the absorbance at 260 nm and 230 nm (A260/A230) provided 
information on chemical (i.e. ethanol) contamination.  The ratio of the absorbance at 260 
nm and 280 nm (A260/A280) provided an estimate of the purity of RNA. Pure 
preparations of RNA displayed an A260/A280 ratio of between 1.8 and 2.0.  
Contamination with proteins or phenol resulted in a lower A260/A280 ratio and 
hampered the accurate quantification of RNA. RNA integrity was determined with ~1 µg 
of total RNA on a 1% agarose gel.  These RNA samples were combined with loading 
buffer (1:1 ratio, Ambion) and incubated for 30 minutes at 50oC in a water bath prior to 
gel electrophoresis.  18s and 28s rRNA bands were visual determinants of the RNA 
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quality and integrity.  Lack of smearing or clumping of bands demonstrated non-
degraded RNA. 
3.5.2  DNA elimination and cDNA synthesis 
One µg RNA from each sample was treated with DNase (Invitrogen) to eliminate 
any genomic contamination and then reverse-transcribed to cDNA, using High Capacity 
cDNA Synthesis kit (Applied Biosystems), following the kit’s instructions.  A 2× reverse 
transcription master mix was prepared using nuclease-free water, 10× RT buffer, 25× 
dNTP mix, 10× Random Primers, RTase, and RNase inhibitor.  cDNA was then 
synthesized in a thermal cycler using the following cycling parameters: 10 minutes at 
25oC, 120 minutes at 37oC, followed by 5 minutes at 85oC.  Freshly synthesized cDNA 
was directly used for PCR quantitative application or stored at 4oC until PCR was 
performed.  To check accurate cDNA synthesis, some cDNA samples were examined on 
a 2% agarose gel composed of TE buffer and Ethitium Bromide.  Four µl of cDNA were 
combined with one µl of Blue Juice Gel Loading buffer (Invitrogen) and examined on the 
gel to visualize cDNA synthesis.    
3.5.3  Quantitative real-time reverse transcriptase-polymerase chain reaction 
(real-time RT-PCR) 
Quantitative real-time RT-PCR was performed using SYBR Green chemistry on 
an ABI StepOne Real-Time PCR System (Applied Biosystems).  PCR reactions were 
performed using 100 ng of cDNA as template, CXCL10 target gene and GAPDH 
endogenous control specific primers, Power SyberGreen, and DEPC-treated water to 
obtain a final volume of 20 µl.  The PCR primers were purchased from 
www.realtimeprimers.com and Invitrogen (Table 3) and were used at a concentration of 
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100 nM per reaction.  Power SYBR Green master mix (Applied Biosystems) was used 
for the SYBR Green PCR reactions.  Standard SYBR Green protocols were followed for 
PCR amplification.  Thermal cycling conditions were 95oC for 10 minutes, followed by 
45 additional cycles of 95oC for 15 seconds, 63oC for 15 seconds, and 72o◦C for 20 
seconds.   
To assure amplification of a single product, a melt curve analysis was performed 
and analyzed for all the SYBR Green real-time PCR reactions.  Reaction products were 
checked on 2% agarose gel to confirm the correct amplicon size generated following 
PCR amplification of each target.  Evaluated expression of several endogenous genes as 
candidates for control genes for relative expression analysis is presented in Table 3.  
Expression of GAPDH was determined to be an appropriate endogenous control for gene 
expression studies.  Primer sequence information for target gene and endogenous controls 
is presented in Table 3.   
 
Table 3:  Primer pairs for SYBR green real-time RT-PCR (realtimeprimers.com 
and Invitrogen) 
Target 
Gene Name 
 
Forward and Reverse primer 
sequence(5'-3') 
Primer 
Tm 
Amplicon 
size Gene Accession 
CXCL10 Fp:AACCTCCAGTCTCAGCACCATGAA Rp:AGGTACAGCGTACGGTTCTAGAGAG 78
oC 112bp NC_000004.11 
HPRT1 Fp: GCTGACCTGCTGGATTACAT Rp:TTGGGGCTGTACTGCTTAAC 58
oC 242bp NM_013556.1 
18S Fp:TTCGAACGTCTGCCCTATCAA Rp:GATGTGGTAGCCGTTTCTCAGG  85
oC 118bp NT_167214.1 
PPIA Fp:AGCTCTGAGCACTGGAGAGA Rp:GCCAGGACCTGTATGCTTTA 58
oC 178bp AK028210 
GAPDH Fp:GAGTCAACGGATTTGGTCGT  Rp:TTGATTTTGGAGGGATCTCG  80
oC 110bp NM_007393.1 
CXCL10:  Interferon-γ-inducible protein 10kDa 
HPRT1:  Hypoxanthinephophoribosyltransferase-1 
PPIA:  Peptidylprolyl isomerase A 
GAPDH:  Glyceraldehyde-3-phosphate dehydrogenase 
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To ensure PCR efficiency, several validation experiments were conducted to 
check the quality of the procedure.  RNA standard curve was prepared for all the targets 
to ensure 90-100% RT efficiency of the reaction for the target.  To assure that 
amplification efficiency fell between 95-100%, experiments were conducted for the set of 
primers using serial-fold dilutions of cDNA in comparison with the endogenous control.  
Also, 2 µl of the PCR product was examined on 2% agarose gel containing 1 µl ethidium 
bromide to visualize the 10 kDa fragment.  Additionally, all PCR experiments were 
performed in duplicates.   
3.5.4 mRNA stability assay 
The measurement of mRNA stability was performed in A172 cells according to 
previously published methods (Maier et al., 2007).  Prior to evaluating the effects of α-
synuclein on mRNA stability, the inhibitory effect of actinomycin D was examined in 
A172 cells.  To examine this, treated cells were exposed to 3, 10, or 30 µg/ml 
actinomycin D, whereas control cells were exposed to an equivalent percent of DMSO 
(since actinomycin D was resuspended in DMSO).  After 1 hour incubation, IL-1β at 
0.25ng/ml was added to all wells (control and treated).  RNA was collected at 30, 60, 90, 
and 180 minutes post-IL-1β and proceeded with PCR (see section 3.5).  When examining 
the effect of α-synuclein on IL-1β-stimulated cells, cells were exposed to desired drug (α-
synuclein) and stimulus (IL-1β at 0.25ng/ml) for 2.5 hours, followed by the removal of 
old media and the addition of fresh serum free media with or without actinomycin D (an 
inhibitor of transcription).  Total RNA was collected at different time points (3, 10, 30, 
60, 90, and 180 minutes) to examine mRNA stability.  CXCL10 mRNA stablity was 
measured by quantitative real time PCR (see section 3.5).   
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3.5.5 Statistical analysis of real time RT-PCR results 
Following qRT-PCR, quantification of gene expression was evaluated by setting 
the threshold cycle in the geometric amplification phase on the plot and setting baseline 
to eliminate any background noise.  Relative quantification of gene expression was 
evaluated by using the comparative computed tomography (CT) method (Hettinger et al., 
2001).  The expression of target gene was normalized to the expression of endogenous 
control GAPDH by subtracting the GAPDH CT value from the corresponding samples 
target CT value (∆CT =CT target-CT endogenous control).  Relative expression was 
calculated using the comparative ∆∆CT (∆∆CT = mean ∆CT of target of treatment group - 
mean ∆CT of target of the calibrator group) method.  Fold changes in relative gene 
expression (RQ) was calculated using 2-∆∆CT.  The results were expressed as relative 
expression of target gene for each treatment group in human astroglial cells.  If ∆CT of 
treatment group was higher in value compared to ∆CT of calibrator group, then RQ was 
calculated using 2-(-∆∆CT).  The value obtained was treated as a negative value, due to less 
amount of mRNA present in the treatment group (higher ∆CT) compared to calibrator 
group (lower ∆CT).  
 
3.6 Analysis of protein expression 
3.6.1 Bicinchoninic acid (BCA) total protein assay 
Levels of total cellular protein content was determined using the bicinchoninic 
acid (BCA) protein assay as previously described (Davis et al., 2002) in order to 
normalize data when appropriate.  A bovine serum albumin (BSA, Sigma A-7638) 
standard curve was prepared using BSA, 2.5 M NaOH, and distilled water (see table 4). 
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Table 4.  Procedure for making BSA standard curve 
Tube # / BSA 
concentration 
Volume of 2.5 M 
NaOH 
Volume of water Volume of BSA (2 
mg/ml) standard 
1 / 0 µg 0.1 ml 0.4 ml -- 
2 / 2 µg 0.1 ml 0.35 ml 0.05 ml 
3 / 4 µg 0.1 ml 0.3 ml 0.1 ml 
4 / 6 µg 0.1 ml 0.25 ml 0.15 ml 
5 / 8 µg 0.1 ml 0.2 ml 0.2 ml 
6 / 12 µg 0.1 ml 0.1 ml 0.3 ml 
7 / 16 µg 0.1 ml -- 0.4 ml 
 
Ten µl in duplicate was pipeted from standard curve tubes into wells B1-H2 in a 96-well 
Falcon plate.  Wells A1 and A2 were left empty for blank.  Ten µl in duplicate was 
pipeted from the unknown samples into wells A3-H12 as needed.  The volume of BCA 
working reagent was calculated (1 part 4% cupric sulfate reagent B plus 50 parts BCA 
reagent A).  For each column on the plate, 2 ml of reagent A (Pierce 23223) was 
prepared.  For example, if there were 2 columns of standard and 2 columns of samples, 
then 4 columns multiplied by 2 ml equaled 8 ml reagent A.  To calculate reagent B 
(Sigma C-2284), divide the total amount of reagent A by 50.  For example, 8 ml was 
divided by 50 to equal 160 µl of reagent B.  Reagent B was first added to a clean multi-
channel pipet container (plastic, V-shaped rectangle) followed by the addition of reagent 
A.  From this solution, 200 µl was pipetted into each well using a 8-channel pippetor.  
Plate was incubated at 37.5oC for 60 minutes, then read at M570 using a BIO-TEK HT 
spectrophotometer. 
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3.6.2 Protein isolation 
Cellular cytoplasmic and nuclear proteins were isolated using the manufacturer’s 
instructions (Active Motif) and kept on ice throughout the protocol.  Because phospho-
IκBα is not highly expressed in A172 cells, duplicate/triplicate wells were pooled 
together during protein extraction. Cells were washed with PBS/phosphatase inhibitors 
(Table 5), removed from plate, and cell suspension was centrifuged for 5 minutes at 500 
rpm (4oC).  The supernatant was discarded and cells were resuspended in 200 µl of 1× 
hypotonic buffer (Table 5).  This resuspension was transferred to pre-chilled 
microcentrifuged tubes and incubated on ice for 15 minutes.  Detergent was added (10 
µl/tube) and tubes were vortexed for 10 seconds.  Tubes were centrifuged for 30 seconds 
at 14,000 × g (4oC) and the supernatant (protein cytoplasmic fraction) was transferred 
into pre-chilled tubes and stored at -80oC until ready to use.  The remaining pellet 
(protein nuclear fraction) was resuspended in 75 µl Complete Lysis Buffer (Table 5) 
followed by 10 seconds of high-speed vortexing.  The suspension was incubated on ice 
for 30 minutes on a rocking platform set at 150 rpm.  After this, the suspension was 
vortexed at high-setting for 30 seconds then centrifuged for 10 minutes at 14,000 × g 
(4oC).  The resulting supernatant (protein nuclear fraction) was transferred into new pre-
chilled tubes and stored at -80oC.   
 
Table 5.  Preparation of buffers (per tube) 
PBS/Phosphatase 
Inhibitors 
0.4 ml of 10× PBS + 3.4 ml of distilled water + 0.2 ml of Phosphatase 
Inhibitors 
1× Hypotonic 
Buffer 
25 µl of 10× Hypotonic Buffer + 225 µl of distilled water 
Complete Lysis 
Buffer 
7.5 µl of 10mM DTT + 66.75 µl of Lysis Buffer AM1 + 0.75 µl of 
Protease inhibitor cocktail 
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3.6.3 CXCL10 ELISA 
A standard dual-antibody solid phase immunoassay (ELISA Development Kit, 
Peprotech) was used for quantification of secreted CXCL10 in cell culture supernatants, 
according to manufacturer’s instructions.   
Table 6.  Preparation of ELISA reagents. 
1× DPBS 1:10 DPBS [10×] in MilliQ water, Store at 4oC 
Wash Buffer 0.05% Tween-20 in 1× DPBS, Prepare 400ml/complete 96-well 
plate (200 µl Tween in 400ml 1× DPBS), Store at 4oC 
Block Buffer 1% BSA in 1× DPBS, Prepare 30ml/complete 96-well plate (300mg 
BSA in 30ml 1× DPBS), Sterile filter and store at 4oC 
Standard Diluent 0.05% Tween-20 and 0.1% BSA in 1× DPBS, Prepare 
50ml/complete 96-well plate (25ul Tween + 50mg BSA in 50ml 1× 
DPBS), Sterile filter and store at 4oC 
Capture Antibody Rabbit anti-hIP-10; Reconstituted stock vial in 0.5 ml sterile water 
for a concentration of 100 µg/ml; resuspended in 1× DPBS 
Detection 
Antibody 
Biotinylated rabbit-hIP-10; Reconstituted stock vial in 0.25 ml 
sterile water for a concentration of 100 µg/ml; resuspended in 1× 
DPBS 
Avidin 
Peroxidase-HRP 
Resuspended in 12 ml standard diluent 
 
The appropriate number of ELISA plates (96-well Falcon) were coated and incubated at 
RT with capture antibody (final concentration of 1 µg/ml, Table 6) the night prior to the 
rest of the ELISA procedure.  The following day, the wells were washed with 200 µl/well 
wash buffer (Table 6) three times and blotted dry on paper towel.  The wells were 
exposed to 300 µl/well block buffer (Table 6) incubated 1 hour at RT.  After incubation 
with block buffer, wells were washed three times with 300 µl wash buffer.   One hundred 
µl of standards (0-2000 pg/ml) and cell culture supernatants was added to appropriate 
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antibody-coated wells of the 96-well plate.  Liquid contents were aspirated and the wells 
washed three times with wash buffer (200 µl). Next, 100 µl of antigen-specific 
biotinylated detection antibody (final concentration of 1 µg/ml, Table 6) was added to 
each well followed by a 2 hour incubation at room temperature.  Wells were aspirated, 
washed three times (200 µl), and exposed to avidin-peroxidase-horseradish peroxidase 
(HRP) conjugate (100 µl, Table 6) and incubated for 30 minutes at room temperature.  
Wells were aspirated and washed three times (200 µl), and 100 µl of ABTS liquid 
substrate solution (Sigma cat. # A3219) was added to each well followed by 10-15 
minute incubation at room temperature.  Absorbance was read at 450 nm (with 
wavelength correction set at 650nm) on the BIO-TEK HT spectrophotometer.   
3.6.4 Chemiluminescent NF-κB p65 and p50 Transcription Factor assays 
The activation of NF-κB was assessed by the nuclear translocation of the NF-κB 
proteins p65 and p50.  The p65 and p50 Transcription Factor kit (Thermo Scientific) was 
used for quantification of active forms of p65 or p50 from cell protein extracts (see 
section 3.6.2) according to the manufacturer’s instructions.  Briefly, 50 µl of working 
binding buffer (Table 7) was added to appropriate streptavidin-coated wells of a 96-well 
plate with bound NF-κB biotinylated-consensus sequence.  Four µl of wild type or 
mutant competitor duplex was added, followed by 5 µl of extract, and 2 µl positive 
control TNFα Activated HeLa cell nuclear extract for 1 hour at room temperature with 
mild agitation.  Liquid contents were aspirated and wells washed three times with 200 µl 
wash buffer (Table 7).  Next, 100 µl of diluted primary antibody (Table 7) was added to 
each well followed by a 1 hour incubation at room temperature without agitation.  Wells 
were aspirated and washed three times.  Diluted secondary antibody (100 µl, Table 7) 
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were added to each well and incubated for 1 hour at room temperature without agitation.  
Wells were aspirated, washed four times, 100 µl of chemiluminescent substrate (Table 7) 
were added to each well and immediately measured (chemiluminescent signal decreases 
with time).  Luminescence was read on the BIO-TEK HT 
luminometer/spectrophotometer.   
Table 7.  Preparation of buffers and antibodies.  Volumes per 96-well plate. 
Working Binding 
Buffer 
4.32 ml of Ultrapure Water + 1.152 ml of 5× NFκB Binding Buffer 
+ 288 µl of 20× Poly dIdC 
Wash Buffer 45 ml of ultrapure water + 5 ml 10× wash buffer 
Primary antibody 
dilution 
12 µl of primary antibody + 12 ml of antibody dilution buffer 
Secondary 
antibody dilution 
1 µl of secondary antibody + 10 ml of antibody dilution buffer 
Chemiluminescent 
solution 
1:1 combination of Luminol/Enhancer Solution (6 ml) and Stable 
Peroxide Solution (6 ml), (each strip requires 0.5 ml of each 
reagent) 
 
3.6.6  Phospho-IκBα (Ser32) Sandwich ELISA assay 
Quanitification of the amount of phosphorylated IκBα (Ser32) from cell protein 
extracts (see section 3.6.2) was measured following manufactorer’s instructions (Cell 
Signaling Technology).  Because phosphorylation of IκBα at Ser32/36 is essential for 
release of active NF-κB, phosphorylation at this site is an excellent marker of NF-κB 
activation.  First, the IκBα capture antibody (100 µl per well at 1:100 in PBS, Table 8) 
was coated in PBS overnight (17-20 hours) at 4oC in 96 well plates.  After overnight 
coating, wells were washed 4 times with wash buffer (200 µl per well, Table 8) and 
blocked for 2 hours at 37oC (150 µl per well, Table 8).  Following blocking, wells were 
washed and 100 µl of cell lysates (see section 3.6.2) was added per well (37oC for 2 
hours).  Wells were washed again and exposed to Phospho-IκBα (Ser32) Detection 
antibody (100 µl per well at 1:100 in PBS) at 37oC for 1 hour.  Afterwards, wells were 
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washed and exposed to secondary anti-rabbit-IgG HRP conjugated antibody (100 µl per 
well at 1:1000 in PBS) for 30 minutes at 37oC.  TMB (Cell Signaling #7004), a HRP 
substrate, was added for color development (100 µl per well) at 37oC for 10 minutes.  
This was followed by the addition of 100 µl of STOP solution (Cell Signaling #7002) per 
well.  Absorbance was read at 450 nm on the BIO-TEK HT spectrophotometer.  The 
absorbance magnitude read is proportional to the quantity of phosphorylated IκBα 
protein. 
 
Table 8.  Preparation of buffers 
Coating Buffer 1× PBS 
Wash Buffer 1× PBS + 0.05% Tween-20 
Blocking Buffer 1× PBS + 0.05% Tween-20 + 1% BSA 
 
3.7 Statistical analysis 
GraphPad Prism version 4 (Graph Pad Software Inc, San Deigo, CA) was used for 
statistical analysis.  Results from independent experiments were combined for 
presentation as the mean + S.E.M. of either actual or percent control values for the 
number (n) of individual samples used for each data point.  One-way ANOVA, post-hoc 
Dunnett’s or Neuman-Keuls’ multiple comparisons were used for parametric analyses.  
Differences at P< 0.05 were considered significant (* P<0.05, ** P<0.01, and *** 
P<0.001). 
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CHAPTER IV 
 
 
RESULTS 
Part I 
 
Alpha-synuclein modulation of inflammatory signaling in TNFα-stimulated  
human A172 astroglial cells 
 
4.1   Aggregation of α-synuclein alters CXCL10 protein expression in human 
A172 astroglial cells 
Lewy bodies, the pathological hallmark of PD, are mainly composed of fibrillary 
α-synuclein polymers.  However, soluble oligomers of α-synuclein are more toxic to 
neurons.  In order to examine the effects of α-synuclein on inflammatory signaling in 
human A172 astroglial cells, purified human α-synuclein was ‘aged’ (aggregated) to 
obtain an inflammatory-inducing conformation.  To decide between a soluble oligomeric 
formation (7 day aging) and fibrillar polymer (14 day aging), the effect of 7- and 14-day  
α-synuclein aging on the modulation of CXCL10 protein expression in human A172 
astroglial cells was assessed (Figures 8, 10, and 12).   
When examining the effects of α-syunclein, acute (24 hour) and chronic (72 hour) 
exposure of this aggregate was explored in human A172 astroglia (Figure 8A and B).  
A172 cells were exposed to a range of α-synuclein concentrations (3.7 -300 nM) in the 
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presence or absence of TNFα (5 ng/ml) (Figures 8-11).  Although minimum CXCL10 
expression was detected in the unstimulated and α-synuclein alone treatment groups, 24 
hour exposure of TNFα alone up-regulated CXCL10 protein expression (Figures 8, 10, 
and 12).  Tumor necrosis factor α-induced CXCL10 production in A172 cells was not 
significantly affected by α-synuclein co-exposed with TNFα at either acute or chronic 
exposures of 7-day α-synuclein aggregation (Figure 8A and B).  Treatments of 7-day α-
synuclein aggregation did not significantly altered astroglial cell viability, as shown in 
Figures 9A and B.  
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Figure 8. Effects of acute and chronic exposures of 7day old α-synuclein on TNFα-induced CXCL10 
expression in A172 cells.  Cells were exposed to (A) acutely (24h) and (B) chronically (72h) to α-
synuclein in the presence or absence of TNFα (5 ng/ml) in serum-free medium for the final 24h.  Minimum 
CXCL10 expression was detected in the unstimulated and α-synuclein alone treatment groups, while 24 
hour exposure of TNFα alone up-regulated CXCL10 protein expression.  Tumor necrosis factor α-induced 
CXCL10 production in A172 cells was not significantly affected by α-synuclein co-exposed with TNFα at 
either acute or chronic exposures of 7-day α-synuclein aggregation.  Levels of secreted CXCL10 protein in 
the media were quantitated by ELISA.  Data presented represent the mean + S.E.M. of duplicate measures 
from 3 independent experiments.  Significant differences were determined by one-way ANOVA with 
Dunnett’s post-hoc comparisons relative to TNFα.  ***P < 0.001 vs TNFα 
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Figure 9. Effect of 7-day old α-synuclein and TNFα on cytotoxicity in human astroglial cells 
cytotoxicity. Cells were exposed to (A) acutely (24h) and (B) chronically (72h) to α-synuclein in the 
presence or absence of TNFα (5 ng/ml) in serum-free medium for 24h.  As shown in (A) and (B), A172 
cells treated with 7-day α-synuclein aggregation did not significantly alter astroglial cell viability.  Cell 
viability was assessed using the MTT assay.  Data presented represent the mean + S.E.M. of 3 measures 
from a single independent experiment.  No significant differences (P>0.05) among treatment were 
determined by one-way ANOVA.   
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The effects of a 14-day aging of α-syunclein resulted in a different trend (Figure 
10A and B).  Although acute and chronic exposure of α-synuclein to A172 cells produced 
minimal CXCL10 protein levels in the absence of TNFα, α-syunclein co-exposed with 
TNFα (final 24 hours) significantly (P<0.05) enhanced TNFα-induced CXCL10 
production in human astroglial cells.  The up-regulation was detected following an acute 
exposure of 11 nM α-synuclein; yet, this effect was lost as the concentration of α-
syunclein increased (33-300 nM) (Figure 10A).  Chronic exposure to 75 and 300 nM α-
syunclein also resulted in an enhancement of CXCL10 expression relative to TNFα 
treated cells (Figure 10B).  The modulation did not appear to be due to cell viability 
variations among treatments (Figure 11).  Examination of TNFα at lower concentrations 
(0.1-2.5 ng/ml) dose-dependently increased the expression of CXCL10 in A172 cells; 
however, the effect of α-syunclein (3.7-33 nM) at the lower TNFα concentrations did not 
enhance the TNFα-induced CXCL10 protein expression (Figure 12A and B).  
Furthermore, data suggest that TNFα at the concentration of 5 ng/ml is required to 
provide a threshold level needed for α-syunclein to have an effect.   
Overall, 14-day aged α-synuclein resulted in significant modulation of the 
production of TNFα-induced CXCL10 protein.  Furthermore, acute exposure of α-
syunclein resulted in a concentration-dependent production of CXCL10 protein.  
Consequently, all subsequent experiments were performed with 24 hour administration of 
α-synuclein aged for 14 days. 
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Figure 10. Effects of acute and chronic exposures of 14-day old α-synuclein on TNFα-induced 
CXCL10 expression in A172 cells.  Cells were exposed to (A) acutely (24h) and (B) chronically (72h) to 
α-synuclein in the presence or absence of TNFα (5 ng/ml) in serum-free medium for 24 h.  Although the 
addition of α-synuclein to A172 cells produced minimal CXCL10 protein levels in the absence of TNFα (A 
and B), α-syunclein co-exposed with TNFα (final 24 hours) significantly enhanced TNFα-induced 
CXCL10 production.  The up-regulation was detected following an acute exposure of 11 nM α-synuclein 
(A), while chronic exposure of 75 and 300 nM α-syunclein also resulted in an enhancement of CXCL10 
expression relative to TNFα treated cells (B).  Levels of secreted CXCL10 protein in the media were 
quantitated by ELISA.  Data presented represent the mean + S.E.M. of 2-3 measures from 1-7 independent 
experiments. Significant differences were determined by one-way ANOVA with Dunnett’s post-hoc 
comparisons relative to TNFα.  *P < 0.05 vs TNFα,  *P < 0.01 vs TNFα , *** P < 0.001 vs TNFα. 
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Figure 11. Effect of 14-day old α-synuclein and TNFα on cytotoxicity in human astroglial cells 
cytotoxicity. Cells were exposed to TNFα (5 ng/ml) in the presence or absence of acute (24h) exposure of 
α-synuclein in serum-free medium for 24 h.  Untreated A172 cells and cells treated with TNFα  +/- α-
synuclein  did not result in differing cell viability levels.  Cell viability was assessed using the MTT assay.  
Data presented represent the mean + S.E.M. of duplicate measures from 5 independent experiments.  No 
significant differences (P>0.05) among treatment were determined by one-way ANOVA.   
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Figure 12. Effects of 14-day old α-synuclein on TNFα-induced CXCL10 expression in A172 cells.  
Cells were exposed to (A) TNFα (0.1 and 0.25 ng/ml) (B) TNFα (1 and 2.5 ng/ml) in the presence or 
absence of α-synuclein (3.7-33 nM) in serum-free medium for 24h.  Examination of TNFα at lower 
concentrations (0.1-2.5 ng/ml) dose-dependently increased the expression of CXCL10 in A172 cells; 
however, the effect of α-syunclein (3.7-33 nM) did not enhance the TNFα-induced CXCL10 protein 
expression (A and B).  Levels of secreted CXCL10 protein in the media were quantitated by ELISA.  Data 
presented represent the mean + S.E.M. of duplicate measures from 3 independent experiments.  Significant 
differences were determined by one-way ANOVA with Dunnett’s post-hoc comparisons relative to TNFα.  
*P < 0.05 vs TNFα, **P < 0.01 vs TNFα , *** P < 0.001 vs TNFα 
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4.2   Increased NF-κB signaling by α-synuclein in TNFα-stimulated human A172 
astroglial cells  
 
The activation of NF-κB was assessed by the nuclear translocation of the NF-κB 
proteins p65 and p50.  CXCL10 expression is regulated in part at the transcriptional level 
by the transcription factor NF-κB.  Levels of active nuclear NF-κB protein p65 were 
evaluated to determine relative NF-κB modulations by α-synuclein.  To determine if the 
14-day aged human α-synuclein has an effect on NF-κB, astroglial cells were exposed to 
the α-synuclein and TNFα treatment that significantly induced protein expression (Figure 
10A).  As shown in Figure 13, unstimulated and 11 nM α-synuclein alone (24 hour) 
resulted in a minimal activation of NF-κB; however, TNFα (5 ng/ml) increased the 
activation as early as 10 minutes post-TNFα exposure.  The enhancement of NF-κB 
activation by TNFα was remained elevated (30 minutes), but co-exposure to α-synuclein 
did not significantly alter this modulation by TNFα (Figure 13).  
Upon further examination using additional α-synuclein concentrations (3.7 and 33 
nM), it was determined that NF-κB activation was significantly up-regulated by α-
synuclein relative to TNFα treated cells (Figure 14A).  Specifically, aggregated α-
synuclein at 3.7 and 33 nM significantly (P<0.001 and P<0.01, respectively) induced NF-
κB activation at 3 minutes (Figure 14A).  However, this effect by α-synuclein was lost at 
subsequent time points of 10 and 30 minutes (Figure 14B and C).  Nuclear factor – κB 
activation was increased in TNFα treated cells, yet showed minimum induction in the 
presence of α-synuclein alone and unstimulated cells (Figure 13 and 14).  
Therefore, 11 nM of α-synuclein did not increase NF-κB activation relative to 
TNFα alone, yet the enhancement of NF-κB activation at the level of p65-DNA binding 
was detected by other α-synuclein concentrations (3.7 and 33 nM) in A172 cells.    
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Figure 13. Alpha-synuclein did not enhance inflammatory-induced active NF-кB signaling protein in 
human A172 astroglial cells.  Cells were exposed to α-synuclein in serum-free medium for 24 h.  Also, 
during the last 3, 10, 30, and 810 min, cells were co-exposed to TNFα (5 ng/ml).   Unstimulated cells and 
cells exposed to 11 nM α-synuclein alone resulted in a minimal activation of NF-κB; however, TNFα 
increased the activation as early as 10 minutes post-TNFα exposure.  The enhancement of NF-κB activation 
by TNFα was remained elevated (30 minutes), but co-exposure to α-synuclein did not significantly alter 
this modulation by TNFα.  Arbitrary binding activity of NF-кB p65 signaling protein was determined 
chemiluminescently using nuclear extracts.  Data presented represent the mean + S.E.M. of duplicate 
measures from 2 independent experiments.  Significant differences were determined by one-way ANOVA 
with Dunnett’s post-hoc comparisons relative to TNFα.  **P < 0.01 vs TNFα , *** P < 0.001 vs TNFα 
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Figure 14. Lower α-synuclein concentration potentiates inflammatory-induced active NF-кB 
signaling protein in human A172 astroglial cells.  Cells were exposed to α-synuclein in serum-free 
medium for 24 h.  Also, during the last 3, 10 and 30min, cells were co-exposed to TNFα (5 ng/ml).  NF–κB 
activation was increased in TNFα treated cells, yet showed minimum induction in the presence of α-
synuclein alone and unstimulated cells (A).  At 3 minutes, aggregated α-synuclein at 3.7 and 33 nM in the 
presence of TNFα significantly (P<0.001 and P<0.01, respectively) induced NF-κB activation (A) relative 
to TNFα alone.  However, this effect by α-synuclein was lost at subsequent time points of 10 and 30 
minutes (B and C).  Arbitrary binding activity of NF-кB p65 signaling protein was determined 
chemiluminescently using nuclear extracts.  Data presented represent the mean + S.E.M. of 2-3 measures 
from 1-4 independent experiments.  Significant differences were determined by one-way ANOVA with 
Dunnett’s post-hoc comparisons relative to TNFα. **P < 0.01 vs TNFα, ***P < 0.001 vs TNFα. 
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4.3 Supplementary Data:  Elevated nitrite production by α-synuclein in 
cytokine-stimulated human A172 astroglial cells  
 
To determine the effects of α-synuclein on iNOS induction, nitrite accumulation 
from treatment media was used as an indicator of inflammatory enzyme activity.  
Stimulation of A172 cells by a cytokine mixture (TNFα + IL-1β + IFNγ) for 24 hours 
resulted in a significant induction of nitrite levels relative to unstimulated cells.  This 
induction was not affected by the addition of α-synuclein (24 hour exposure) at 
concentrations ≤100 nM, as indicated by no significant change in nitrite production 
relative to cytokine mixture (Figure 15).  Conversely, the presence of 300 nM 
significantly (P<0.05) potentiated the amount of nitrite production induced by the 
cytokine mixture.  As shown in Figure 15, unstimulated cells only produced minimal 
nitrite.   
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Figure 15. Alpha-synuclein enhanced inflammatory-induced nitrite production in human A172 
astroglial cells.  Cells were exposed to α-synuclein and co-exposed to TNFα (30 ng/ml), IL-1β (5 ng/ml), 
and IFNγ (100 ng/ml) for 24h.  A172 cells stimulated by the cytokine mixture resulted in a significant 
induction of nitrite levels relative to unstimulated cells.  This induction was not affected by the addition of 
α-synuclein (24 hour exposure) at concentrations ≤100 nM; however, α-synuclein at 300 nM significantly 
(P<0.05) potentiated the amount of nitrite production induced by the cytokine mixture.  Nitrite 
accumulation in the culture media was determined spectrophotometrically using the Griess reagent. Data 
were normalized as percent control within each independent experiment and represent the mean + S.E.M. 
of 1-2 measures from 2 independent experiments. Significant differences were determined by one-way 
ANOVA with Dunnett’s post-hoc comparisons.   *P < 0.05 vs control. 
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Part II 
 
Alpha-synuclein modulation of inflammatory signaling in IL-1β-stimulated 
human A172 astroglial cells 
 
 
4.4 Enhancement of CXCL10 protein expression by α-synuclein on IL-1β-
induced CXCL10 expression in human A172 astroglial cells 
 
To assess α-synuclein’s effect on the production of CXCL10 induced from 
another critical PD inflammatory mediator, IL-1β-stimulated astrocytes were exposed to 
concentrations of α-synuclein (3.7-33 nM) and analyzed relative to IL-1β alone.  Under 
unstimulated conditions, CXCL10 protein production was constitutively expressed at 
very low levels (Figure 16).  Minimum expression of this chemokine was demonstrated 
by α-synuclein alone treatments (24 hour exposure, Figure 10A).  When astroglial cells 
were exposed to IL-1β for 24 hours, results demonstrated an enhanced chemokine 
production at ≥ 0.25 ng/ml relative to unstimulated cells.  When cells were co-exposed to 
both α-synuclein and IL-1β for 24 hours, α-synuclein at 33 nM significantly potentiated 
IL-1β (0.25 ng/ml)-induced CXCL10 expression.  The up-regulation was not due to 
variations in cell viability among treatments (Figure 17).  However, enhancement of 
CXCL10 protein by α-synuclein was not continued with higher IL-1β concentrations (1 
and 5 ng/ml, Figure 16B).  Therefore, the data suggest that α-synuclein significantly up-
regulated IL-1β-induced CXCL10 production, however, this effect by α-synuclein was 
lost as the concentration of IL-1β increased.       
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Figure 16. Effects of α-synuclein on IL-1β-induced CXCL10 expression in A172 cells.  Cells were 
exposed to IL-1β at (A) 0.1 and 0.25 ng/ml and (B) 1 and 2.5 ng/ml in the presence or absence of α-
synuclein (3.7-33 nM) in serum-free medium for 24 h.  Under unstimulated and α-synuclein alone 
conditions, minimum expression of CXCL10 protein was expressed (A).  Astroglial cells were exposed to 
IL-1β resulted in an enhanced chemokine production at ≥ 0.25 ng/ml relative to unstimulated cells.  Alpha-
synuclein at 33 nM significantly potentiated IL-1β (0.25 ng/ml)-induced CXCL10 expression in cells co-
exposed to both α-synuclein and IL-1β.  This up-regulation by α-synuclein was not seen continued with 
higher IL-1β concentrations (B).  Levels of secreted CXCL10 protein in the media were quantitated by 
ELISA.  Data presented represent the mean + S.E.M. of duplicate measures from 3 independent 
experiments.  Significant differences were determined by one-way ANOVA with Dunnett’s post-hoc 
comparisons.  *P < 0.05 vs IL-1β, ***P < 0.05 vs IL-1β. 
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Figure 17. Effect of α-synuclein and IL-1β on cytotoxicity in human astroglial cells cytotoxicity. Cells 
were exposed to IL-1β (0.25 ng/ml) in the presence or absence of α-synuclein (3.7-33 nM) in serum-free 
medium for 24 h.  Untreated A172 cells and cells treated with IL-1β  +/- α-synuclein  did not result in 
differing cell viability levels.  Cell viability was assessed using the MTT assay.  Data presented represent 
the mean + S.E.M. of triplicate measures from 2 independent experiments. No significant differences 
(P>0.05) among treatment were determined by one-way ANOVA.   
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4.5 Alpha-synuclein did not modulate IL-1β-induced CXCL10 mRNA expression 
in human A172 cells 
To identify the role of α-synuclein on CXCL10 mRNA expression, astroglial cells 
were exposed to IL-1β and α-synuclein over several time periods.  The experiments used 
concentrations of IL-1β and α-synuclein that induced significant CXCL10 protein 
expression (Figure 16A) and were analyzed relative to CXCL10 mRNA expression levels 
observed by IL-1β at the 2-hour time point.  Initially identifying the effects of IL-1β 
alone on chemokine mRNA, results demonstrated a time-dependent effect of this 
cytokine at 0.25 ng/ml on CXCL10 mRNA expression (Figure 18A).  As illustrated in 
Figure 18A, IL-1β potentiated the expression of CXCL10 mRNA in astroglia and peaked 
at 8 hours post-exposure.  CXCL10 mRNA expression produced by IL-1β at later time 
points (≥16 hours) returned to levels similar to 2 hour post-treatment.  When cells were 
co-exposed with 33 nM α-synulcein and IL-1β, significant alterations of inflammatory-
induced chemokine mRNA expression by α-synuclein were not detected (Figure 18B).  
Furthermore, other α-synulcein concentrations (3.7 and 11 nM) did not significantly alter 
IL-1β-induced CXCL10 mRNA expression (Figure 18B).  
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Figure 18.  Effect of α-synuclein on IL-1β-stimulated CXCL10 mRNA expression in human astroglial 
cells. Cells were exposed to (A) IL-1β (0.25 ng/ml) alone or (B) in the presence of α-synuclein (3.7-33 nM) 
in serum-free medium for indicated hours.  CXCL10 mRNA levels were potentiated by IL-1β in astroglia 
with a peak at 8 hours post-exposure (A).  The addition of α-synuclein (at all concentrations) to IL-1β-
stimulated cells did not significantly alter IL-1β-induced CXCL10 mRNA expression (B).  CXCL10 and 
GAPDH mRNA was assessed using quantitative real time RT-PCR.  Data were normalized to GAPDH 
within each independent experiment and expressed as relative induction of IL-1β at 2 h post-treatment.  
Data presented represent the mean + S.E.M. of duplicate measures from 4-8 independent experiments.  
Significant differences among treatment were determined by one-way ANOVA with Dunnett’s post-hoc 
comparisons.   *P < 0.05 vs IL-1β, **P < 0.01 vs IL-1β. 
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4.6   Alpha-synuclein mediates the stability of IL-1β-induced CXCL10 mRNA in 
human A172 cells 
CXCL10 protein expression was increased in the presence of α-synuclein, 
whereas the mRNA accumulation was not affected by this protein.  Therefore, the 
induction of CXCL10 protein by α-synuclein may be mediated, in part, by an increase in 
mRNA stability.  To determine whether α-synuclein mediates CXCL10 mRNA stability, 
A172 cells were exposed to the transcription inhibitor actinomycin D at varying times to 
inhibit de novo mRNA synthesis.  It was first necessary to verify the effectiveness of 
actinomycin D in human A172 cells prior to initiating α-synuclein experiments.  Human 
A172 cells were pre-treated with either actinomycin D (3, 10, 30 µg/ml) or control 
vehicle (3, 10, 30 µg/ml DMSO) 1 hour prior to the addition of IL-1β (0.25 ng/ml) 
(Figure 19).  Data was analyzed relative to CXCL10 mRNA expression levels observed 
by the IL-1β-only treatment that ran concurrently with the pretreatments.  Treatment 
groups of cells exposed to IL-1β in the presence of control vehicle showed a gradual 
increase of CXCL10 mRNA, with significant mRNA levels detected at 120 minutes post-
treatment (Figure 19).  A172 cells pre-treated with actinomycin D inhibited the synthesis 
of CXCL10 mRNA transcription relative to IL-1β with DMSO treatments, and 
significant inhibition by actinomycin D was observed at earliest time point (30 minutes) 
and across time.  Consequently, the transcription of de novo CXCL10 mRNA transcripts 
in A172 cells is effectively inhibited by actinomycin D, as demonstrated in Figure 19.   
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a, b,c  represent statistical analysis within treatment group IL-1β + DMSO (3,10,30 µg/ml) across time 
α, β, ε  represent statistical analysis within treatment group IL-1β + ActD (3,10,30 µg/ml) across time 
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Figure 19. Inhibition of de novo CXCL10 mRNA transcription by actinomycin D in IL-1β-stimulated 
human astroglial cells. Cells were pretreated with DMSO or ActD (3,10,30 µg/ml) in serum-free medium 
one hour prior to the addition of IL-1β (0.25 ng/ml) for the indicated times.  Concurrent to 1 h pretreatment, 
IL-1β alone treatment also ran for one hour.  Cells exposed to IL-1β in the presence of control vehicle 
showed a gradual increase of CXCL10 mRNA, with significant mRNA levels detected at 120 minutes post-
treatment.  A172 cells pre-treated with actinomycin D inhibited the synthesis of CXCL10 mRNA 
transcription relative to IL-1β with DMSO treatments, with significant inhibition by actinomycin D at the 
earliest time point (30 minutes) and across time.  CXCL10 and GAPDH mRNA was assessed using 
quantitative real time RT-PCR.  Data were normalized to GAPDH within each independent experiment and 
expressed as relative induction of IL-1β alone (1 h treatment).  Data presented represent the mean + S.E.M. 
of duplicate measures from 2 independent experiments.  Lines and time points with different superscript 
letters/symbols are significantly (P < 0.05) different as determined by one-way ANOVA with Newman-
Keul’s post-hoc comparisons.   
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Next, actinomycin D was used to examine possible post-transcriptional effects of 
α-synuclein on CXCL10 mRNA stability (Figure 20).  CXCL10 mRNA production was 
induced by a 2.5 hour pretreatment of either IL-1β (0.25 ng/ml) or α-synuclein (33 nM) 
with IL-1β in order to produce adequate mRNA production.  Because the use of 10 µg/ml 
concentration of actinomycin D on astroglia was consistant with others (Gardner et al., 
2006; Kasahara et al., 1991; Yao et al., 2005), this concentration was used to examine α-
synuclein’s role on stability.  After the pretreatment, media was replaced with fresh 
serum-free media in the presence or absence of actinomycin D (10 µg/ml).  A172 cells 
were exposed to actinomycin D for various time points (3 – 270 minutes) and the amount 
of CXCL10 mRNA was determined and relatively quanified to IL-1β at the 0 time point 
(Figure 20).  Results showed no difference of CXCL10 mRNA levels between IL-1β and 
IL-1β with α-synuclein in the absence of actinomycin D.  Conversely, the addition of 
actinomycin D to treatments resulted in a time-dependent decrease in CXCL10 mRNA 
with a significant mRNA decay detected by 30 minutes.  However, less decay was seen 
over time when α-synuclein was present.  Specifically, significantly less mRNA decay 
was detected in the α-synuclein+IL-1β treatment relative to IL-1β at 270 minutes post-
actinomycin D treatment (Figure 20).  Overall, the observations reveal that α-synuclein 
exerts post-transcriptional effects which contribute to increased CXCL10 mRNA stability 
in human A172 cells (Figure 20).  
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Figure 20. Effect of α-synuclein on CXCL10 mRNA stability in IL-1β-stimulated human astroglial 
cells. Cells were pretreated with IL-1β (0.25 ng/ml) in the presence or absence of α-synuclein (33 nM) for 
2.5 h.  Actinomycin D or DMSO (3,10,30 µg/ml) was exposure to cells in fresh serum-free medium for the 
indicated times.  CXCL10 mRNA levels between IL-1β and IL-1β with α-synuclein in the absence of 
actinomycin D showed no difference.  Conversely, the addition of actinomycin D to treatments resulted in a 
time-dependent decrease in CXCL10 mRNA with a significant mRNA decay detected by 30 minutes.  Less 
decay was seen over time when α-synuclein was present compared to IL-1β with actinomycin D alone, 
specifically at 270 minutes post-actinomycin D treatment.   CXCL10 and GAPDH mRNA was assessed 
using quantitative real time RT-PCR.  Data were normalized to GAPDH within each independent 
experiment and expressed as relative induction of IL-1β at 0 time point.  Data presented represent the mean 
+ S.E.M. of duplicate measures from 2 independent experiments. Lines and time points with different 
superscript letters/symbols are significantly (P < 0.05) different as determined by two-way and one-way 
ANOVA with Newman-Keul’s post-hoc comparisons.   
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4.7  Alpha-synuclein does not affect NF-κB signaling in IL-1β-stimulated human 
A172 astroglial cells  
4.7.1 Levels of I-κBα phosphorylation were not enhanced by α-synuclein 
 
CXCL10 expression is regulated in part at the transcriptional level by the 
transcription factor NF-κB.  Levels of phosphorylated I-κBα were evaluated to determine 
relative NF-κB modulations by α-synuclein (Figure 21).  A172 astroglial cells were 
exposed to the α-synuclein and IL-1β treatment that significantly induced CXCL10 
protein expression (Figure 16A).  The presence of IL-1β resulted in no significant 
enhancement in the levels of phosphorylated I-κBα in A172 cells relative to unstimulated 
cells.  Moreover, astroglial cells co-exposed with both IL-1β and α-synuclein did not 
result in a significant modulation of phosphorylated I-κBα levels relative to IL-1β-
induced levels (Figure 21).   
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Figure 21. Effects of α-synuclein on phosphorylated I-κBα levels in human A172 astroglial cells.  
Cells were exposed to α-synuclein in serum-free medium for 24 h.  Also, during the last 2, 5, 10, and 30 
min, cells were co-exposed to IL-1β (0.25 ng/ml).  No significant enhancement in the levels of 
phosphorylated I-κBα in A172 cells were observed in the presence of IL-1β relative to unstimulated cells.  
Astroglial cells co-exposed with both IL-1β and α-synuclein did not result in a significant modulation of 
phosphorylated I-κBα levels relative to IL-1β-induced levels.  Levels of phosphorylated I-κBα were 
quantitated by ELISA.  Data were normalized as percent control within each independent experiment and 
represent the mean + S.E.M. of duplicate measures from 1-3 independent experiments.  No significant 
differences (P>0.05) among treatment were determined by one-way ANOVA.   
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4.7.2 Alpha-synuclein does not alter NF-κB activation 
 
Further examination of the effects of α-synuclein on NF-κB signaling in A172 
cells was investigated via the levels of active nuclear NF-кB p65 and p50 proteins 
(Figure 22).  Nuclear extracts of NF-κB p65 and p50 were at basal levels in unstimulated 
astroglial cells (Figure 22A).  The addition of IL-1β to A172 cells enhanced p50 nuclear 
levels and greatly potentiated p65 nuclear levels.  The induction of active NF-κB proteins 
by IL-1β was observed by 30 minutes and resulted in a peak increase in p65 protein by 60 
minutes.  Results on active p65/p50 from A172 cells co-exposed with α-synuclein and 
IL-1β overlap results from IL-1β-only treatments and therefore, present no significant 
fluctuations by α-synuclein on NF-κB proteins compared to IL-1β alone (Figure 22B).  
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Figure 22. Alpha-synuclein did not alter IL-1β-induced increases in nuclear levels of active NF-кB 
signaling proteins in human A172 astroglial cells.  Cells were unstimulated or exposed to α-synuclein for 
24 h in serum-free medium and co-exposed to IL-1β (0.25 ng/ml) during the last 2-180 minutes of 
treatment.  Nuclear extracts of NF-κB p65 and p50 were at basal levels in unstimulated astroglial cells, and 
the addition of IL-1β enhanced p50 nuclear levels and greatly potentiated p65 nuclear levels (A).  Levels of 
active p65/p50 from A172 cells co-exposed with α-synuclein and IL-1β overlap results from IL-1β-only 
treatments and reveal no significant fluctuations by α-synuclein on NF-κB proteins compared to IL-1β 
alone (B). Arbitrary binding activity of NF-кB p65 and p50 signaling proteins were determined 
chemiluminescently using nuclear extracts.  Data presented represent the mean + S.E.M. of duplicate 
measures from 2-4 independent experiments.  Significant differences among treatments were determined by 
one-way ANOVA with Newman-Keul’s post-doc comparisons.  Letters and asterisks represent statistical 
differences in (A) IL-1β and (B) IL-1β + syn treatments.  *P<0.05, **P<0.01, α = 10 vs. 30 minutes, β = 30 
vs. 60 minutes, δ = 60 vs. 180 minutes. 
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4.8 Supplementary Data:  Alpha-synuclein does not modulate IL-1β-induced 
CXCL10 protein expression in Normal Human Astrocytes 
Concurrent to investigating the effects of α-synuclein in human A172 cells, 
experiments examining the effects of α-synuclein in NHA were also investigated.  
Specifically, α-synuclein’s effect on CXCL10 protein expression was examined in NHA 
(Figures 23A and B), with observations resulting in minimum protein induction in 
unstimulated cells and an up-regulation of CXCL10 expression after a 24-hour treatment 
of IL-1β (0.1-5 ng/ml).  The addition of α-synuclein (3.7, 11, 33 nM) to IL-1β-stimulated 
NHA cells did not result in significant CXCL10 protein modulations compared to IL-1β-
induced CXCL10 protein levels (Figure 23A and B).      
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Figure 23. Effect of α-syncuelin on IL-1β-induced CXCL10 expression in NHA cells.  Cells were 
exposed to IL-1β at (A) 0.1 and 0.25 ng/ml or (B) 1 and 5 ng/ml concentrations in the presence or absence 
of α-synuclein (3.7,11,33 nM) in serum-free medium for 24 h.  Minimum CXCL10 protein induction was 
observed in unstimulated cells, with an up-regulation of chemokine expression after a 24-hour treatment of 
IL-1β (0.1-5 ng/ml) (A and B).  NHA cells co-exposed to α-synuclein (3.7, 11, 33 nM) and IL-1β did not 
result in significant CXCL10 protein modulations compared to IL-1β-induced CXCL10 protein levels (A 
and B).  Levels of secreted CXCL10 protein in the media were quantitated by ELISA.  Data presented 
represent the mean + S.E.M. of triplicate measures from 3-4 independent experiments.  Significant 
differences were determined by one-way ANOVA with Dunnett’s post-hoc comparisons.  ***P < 0.05 vs 
control. 
 
B 
A 
85 
 
Part III 
 
Neuromelanin and oxidized dopamine modulation of inflammatory signaling in  
TNFα-stimulated human A172 astroglial cells 
 
4.9 Neuromelanin and oxDA inhibit CXCL10 expression in A172 astroglial cells 
The effect of other PD-associated molecules, NM and oxDA, were also examined 
in human A172 astroglial cells in this study.  When A172 cells were unstimulated, cells 
produced constitutive levels of CXCL10 protein (Figure 24).  Also, cells exposed to NM- 
or oxDA-only treatments did not produce altered chemokine levels relative to 
unstimulated cells (Figure 24A and B).  However, consistent with Figures 8 and 10, 
TNFα (5 ng/ml) significantly enhanced the expression of CXCL10 protein in A172 cells.  
Treatment groups of ≤ 3.7 µM oxDA with TNFα did not affect TNFα-induced CXCL10 
production (Figure 24A); however, a significant reduction (75%) in CXCL10 expression 
was observed in response to 300 µM oxDA relative to TNFα alone.  Cytotoxicity in A172 
astroglial cells was observed at 300 µM in the presence of TNFα but resulted in only a 
10% decrease in viability (Figure 25A).  Nonetheless, the reduction in CXCL10 protein 
expression by 300 µM oxDA may, in part, be due to less viable cells.  Significant 
reduction in protein expression was also observed in A172 cells exposed to 75 and 150 
µM oxDA in the presence of TNFα, with no alterations on cell viability (Figure 25A). 
Slight differences in CXCL10 production were observed at ≤ 5 µg/ml NM (Figure 
24B); however, only15 µg/ml NM caused a significant reduction (30%) in CXCL10 
levels.  No significant alterations in astroglial cell viability were seen from NM 
treatments (Figure 25B).  
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Figure 24. Effects of oxidized dopamine (oxDA) and neuromelanin (NM) on TNFα-induced CXCL10 
expression in A172 cells.  Cells were exposed to (A) oxDA or (B) NM in serum-free medium for 72 h. 
Also, during the last 24 h, cells were co-exposed to TNFα (5 ng/ml).  Unstimulated A172 cells produced 
constitutive levels of CXCL10 protein (A and B) and neither NM nor oxDA-only treatments altered the 
production (A and B).  TNFα (5 ng/ml) did enhance the expression of CXCL10 protein (A and B), with a 
significant reduction in CXCL10 expression observed at 300 µM oxDA (A) and 15 µg/ml NM (B) relative 
to TNFα alone.  Levels of secreted CXCL10 protein in the media were quantitated by ELISA.  Data were 
normalized as percent control within each independent experiment and represent the mean + S.E.M. of 
triplicate measures from 3-4 independent experiments.  Significant differences were determined by one-
way ANOVA with Dunnett’s post-hoc comparisons.  *P < 0.05 vs TNFα; **P < 0.01 vs TNFα, ***P < 
0.001 vs TNFα. 
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Figure 25. Oxidized dopamine-  and neuromelanin-induced cytotoxicity in TNFα-stimulated human 
astroglial cells. Cells were exposed to (A) oxDA or (B) neuromelanin in serum-free medium for 72 h.  
Also, during the last 24 h, cells were co-exposed to TNFα (5 ng/ml).  Cytotoxicity in A172 astroglial cells 
was observed at 300 µM oxDA in the presence of TNFα (A).  NM treatments did not significantly alter 
astroglial cell viability, as seen in (B).  Cell viability was assessed using the MTT assay.  Data were 
normalized as percent control within each independent experiment and represent the mean + S.E.M. of 2-4 
measures from 2-5 independent experiments for each cell type.  Significant differences were determined by 
one-way ANOVA with Newman-Keul’s post-hoc comparisons.  **P < 0.01 vs TNFα. 
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4.10 Neuromelanin and oxDA down-regulate NF-κB activation in TNFα-
stimulated A172 astroglial cells 
The activation of NF-κB was assessed by the nuclear translocation of the NF-κB 
proteins p65 and p50.  Examination of the effects of TNFα on NF-κB activation was 
conducted to determine the optimal time for NF-κB activation by TNFα for subsequent 
experiments.  Nuclear levels of NF-κB were used as an indicator of NF-κB activation.  
As seen in Figure 26, TNFα potentiated the levels of NF-κB in a time-dependent manner 
in A172 cells.  Specifically, NF-κB activity initially peaked at 10 minutes, with elevation 
seen at 3 minutes and reduction at 810 minutes. 
Next, the examination of the effects of oxDA and NM on NF-кB activation in 
A172 cells was observed (Figures 27 and 28).  Induction of NF-кB activation by the 
cytokine TNFα at a median peak time of 30 minutes was examined in the presence of 
oxDA and NM (Figures 27 and 28).  Activation of NF-кB was not affected by oxDA or 
NM alone compared to the unstimulated cells as indicated by no significant change in 
nuclear levels of NF-кB (Figures 27 and 28).  Conversely, oxDA decreased TNFα-
induced NF-кB activation in astroglial cells between 60-75% relative to TNFα alone 
(Figure 27).  However, the reduction in activation may be due to a decrease in viable cells 
by 300 µM oxDA (Figure 25A).  Neuromelanin also decreased TNFα-induced NF-кB 
activation in A172 cells, as presented by a reduction in nuclear p65 levels (Figure 28A), 
yet similar reduction was not observed for nuclear p50 levels (Figure 28B).  
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Figure 26. Time-dependent response of TNFα to active NF-кB p65 signaling protein in human A172 
astroglial cells.  Cells were exposed to TNFα (5 ng/ml) in serum-free medium for the time course ranging 
from 3 to 810 minutes.  TNFα potentiated the levels of NF-κB in a time-dependent manner in A172 cells, 
with elevation seen at 3 minutes, peaks from 10-90 minutes, and reduction at 810 minutes.  Arbitrary 
binding activity of NF-кB p65 and p50 signaling proteins were determined chemiluminescently using 
nuclear extracts. Data presented represent the mean + S.E.M. of duplicate measures from 2-4 independent 
experiments.  Significant differences were determined by one-way ANOVA with Dunnett’s post-hoc 
comparisons.  *P < 0.05 vs TNFα, **P < 0.01 vs TNFα. 
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Figure 27. Oxidized dopamine decreased TNFα-induced NF-кB activation in human A172 astroglial 
cells.  Cells were exposed to oxDA in serum-free medium for 72 h.  Also, during the last 30min, cells were 
co-exposed to TNFα (5 ng/ml).  Activation of NF-кB was not affected by oxDA alone compared to 
unstimulated cells (A and B), however, oxDA decreased TNFα-induced NF-кB activation in astroglial cells 
between 60-75% relative to TNFα alone (A and B).  NF-κB activation was assessed by using transcription 
factor assay which measures levels of active NF-κB.  Arbitrary binding activity of NF-кB p65 and p50 
signaling proteins were determined chemiluminescently using nuclear extracts. Data were normalized as 
percent control within each independent experiment and represent the mean + S.E.M. of duplicate measures 
from two independent experiments.  Significant differences were determined by one-way ANOVA with 
Dunnett’s post-hoc comparisons.  ***P < 0.001 vs TNFα. 
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Figure 28. Neuromelanin reduced TNFα-induced NF-кB activation in human A172 astroglial cells.  
Cells were exposed to NM in serum-free medium for 72 h.  Also, during the last 30 minutes, cells were co-
exposed to TNFα (5 ng/ml).  NF-кB activation was not affected by NM alone compared to the unstimulated 
cells, as seen in A and B.  However, NM in the presence of TNFα decreased TNFα-induced nuclear p65 
levels (A), yet similar reduction was not observed for nuclear p50 levels (B).  NF-κB activation was 
assessed by using transcription factor assay which measures levels of active NF-κB.  Arbitrary binding 
activity of NF-кB p65 and p50 signaling proteins were determined chemiluminescently using nuclear 
extracts.  Data were normalized as percent control within each independent experiment and represent the 
mean + S.E.M. of duplicate measures from 2 independent experiments. Significant differences were 
determined by one-way ANOVA with Dunnett’s post-hoc comparisons.  ***P < 0.001 vs TNFα. 
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4.11 Supplementary data:   
 4.11.1  Oxidized dopamine- and neuromelanin-induced cytotoxicity in human 
neuronal and/or glial cells.  
In this inflammatory model where cells were co-exposed to oxDA and TNFα, 
oxDA was more toxic to SK-N-SH neuronal cells than to glia (Figure 29).  As shown in 
Figure 29A, ≥ 300 µM oxDA was cytotoxic (approximately 45-75% decrease in viability) 
in neuronal cells compared to TNFα alone.  Furthermore, in CHME-5 microglia cells, 
cytotoxicity was observed with a 20% reduction in viability in cultures exposed to ≥ 300 
µM (Figure 29B).   
When cells were exposed to NM with co-exposure to TNFα, NM was more toxic 
to SK-N-SH neuronal cells than to glia (Figure 30). The number of viable SK-N-SH cells 
compared to TNFα alone was significantly reduced by ≥ 5 µg/ml NM (Figure 30A).  At 
the highest concentration of NM tested (15 µg/ml), there was a 40% decrease in viable 
SK-N-SH cell number.  In comparison, exposure to NM (0.02-15 µg/ml) did not 
significantly alter viability in CHME-5 cultures (Figure 30B).   
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Figure 29. Oxidized dopamine-induced cytotoxicity in human neuronal and glial cells. Cells were 
exposed to oxDA in serum-free medium for 72 h.  Also, during the last 24 h, cells were co-exposed to 
TNFα (5 ng/ml).  oxDA concentrations of ≥ 300 µM were found to be cytotoxic to neuronal cells (45-75% 
decrease, A) and CHME-5 microglial cells (20% reduction, B) compared to TNFα alone.  Cell viability was 
assessed using the MTT assay. Data were normalized as percent control within each independent 
experiment and represent the mean + S.E.M. of 2-4 replicate measures from 4-5 independent experiments 
for each cell type.  Significant differences were determined by one-way ANOVA with Newman-Keul’s 
post-hoc comparisons.  **P < 0.01 vs TNFα. 
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Figure 30. Neuromelanin-induced cytotoxicity in TNFα-stimulated human neuronal and glial cells. 
Cells were exposed to neuromelanin in serum-free medium for 72 h.  Also, during the last 24 h, cells were 
co-exposed to TNFα (5 ng/ml).  For neuronal cells, the number of viable SK-N-SH cells compared to TNFα 
alone was significantly reduced (40% decrease) by ≥ 5 µg/ml NM (A).  Exposure to NM (0.02-15 µg/ml) 
did not significantly alter viability in CHME-5 cultures (B).  Cell viability was assessed using the MTT 
assay.  Data were normalized as percent control within each independent experiment and represent the 
mean + S.E.M. of triplicate measures from 2-3 independent experiments for each cell type.  Significant 
differences were determined by one-way ANOVA with Newman-Keul’s post-hoc comparisons.  **P < 
0.01 vs TNFα. 
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4.11.2  Oxidized dopamine and neuromelanin enhance TNFα-induced iNOS 
induction in human astroglial cells 
To determine the effects of oxDA and NM on iNOS induction, nitrite 
accumulation was used as an indicator of iNOS activity.  Minimal nitrite production was 
detected from A172 cells by TNFα-alone treatments (Figure 31A) and by oxDA- and 
NM-alone treatments (data not shown).  The effect of oxDA on cytokine mixture-induced 
nitrite production was observed and resulted in no significant modulation of iNOS 
induction relative to cytokine mixture alone (Figure 31B).  Conversely, oxDA at ≥ 100 
µM significantly potentiated TNFα-induced iNOS induction (Figure 31A).  Similarly, 
induction of iNOS was potentiated by 0.2-5 µg/ml NM, however lower (0.06 µg/ml) and 
higher (15 µg/ml) NM concentrations had minimal effect on iNOS induction (Figure 32). 
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Figure 31. Oxidized dopamine enhances TNFα-induced nitrite production in human A172 astroglial 
cells.  Cells were exposed to oxDA for 72 h.  Also, during the last 24 h, cells were co-exposed to (A) TNFα 
(5 ng/ml) or (B) a cytokine mixture containing TNFα (30 ng/ml), IFNγ (100 ng/ml), and IL-1β (5 ng/ml).  
Nitrite production from A172 cells was minimal by TNFα-alone treatments (A), however, oxDA at ≥ 100 
µM significantly potentiated TNFα-induced iNOS induction (A).  The effect of oxDA on cytokine mixture-
induced nitrite production resulted in no significant modulation of iNOS induction relative to cytokine 
mixture alone (B).  Nitrite accumulation in the culture media was determined spectrophotometrically using 
the Griess reagent. Data represent the mean + S.E.M. of triplicate measures from 2-4 independent 
experiments. Significant differences were determined by one-way ANOVA with Dunnett’s post-hoc 
comparisons.   ***P < 0.001 vs TNFα. 
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Figure 32. Neuromelanin enhances TNFα-induced nitrite production in human A172 
astroglial cells.  Cells were exposed to NM for 72 h.  Also, during the last 24 h, cells were co-exposed to 
TNFα (5 ng/ml).  Although the lower (0.06 µg/ml) and higher (15 µg/ml) NM concentrations had minimal 
effect on iNOS induction , 0.2-5 µg/ml NM potentiated iNOS expression relative to TNFα alone.  Nitrite 
accumulation in the culture media was determined spectrophotometrically using the Griess reagent. Data 
represent the mean + S.E.M. of quadruplicate measures from 3 independent experiments. Significant 
differences were determined by one-way ANOVA with Dunnett’s post-hoc comparisons.   **P < 0.01 vs 
TNFα, ***P < 0.001 vs TNFα. 
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CHAPTER V 
 
 
DISCUSSION 
Part I 
 
Alpha-synuclein modulation of inflammatory signaling in cytokine-stimulated 
human A172 astroglial cells 
 
 
5.1 Alpha-synuclein enhanced cytokine-stimulated CXCL10 expression in 
human A172 astroglial cells 
Parkinson’s disease studies reveal an up-regulation of α-synuclein with extensive 
oligomeric forms elevated in the cerebrospinal fluid and blood plasma of PD patients 
compared to healthy controls (El-Agnaf et al., 2003; El-Agnaf et al., 2006).  
Neuroinflammation is also observed in PD, with an increase in proinflammatory 
cytokines and chemokines (Forno et al., 1992; Hunot and Hirsch, 2003; Miklossy et al., 
2006).  Astrocytes are the major cellular source of chemokine production in the CNS and 
demonstrate increased reactive astrocytosis in PD (Teismann and Schulz, 2004).  
Understanding α-synuclein’s effects on astrocytes in the presence of on-going 
inflammation is therefore potentially important.  The two-hit (neuroinflammation and α-
synuclein) in vitro model created for this study mimics PD etiology and produces novel 
attributes to PD research. 
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First, the role of α-synuclein aging was examined to obtain information on the 
length of time for aggregation for astroglial studies.  Initial studies determined that 7-day 
aggregation was not sufficient to significantly modulate TNFα-induced chemokine 
protein expression.  The current data suggest that longer than seven days is needed to 
generate a molecule that is proinflammatory in this A172 model.  This is consistant with 
a study by Zhang and colleagues (2005), who characterized aged α-synuclein by a size 
exclusion column.  Zhang et al. (2005) determined the nature of human α-synuclein and 
found 7 days of aging formed α-synuclein aggregates between 44 and 158 kDa, which is 
consistent with a soluble oligomer conformation.  Fourteen days of aging formed α-
synuclein aggregates sized > 670 kDa, which represent fibrillary α-synuclein 
conformation (Zhang et al., 2005).  Although oligomer α-synuclein is more toxic to 
neurons than fibrillary polymers, Lewy bodies (which are the pathological hallmark of 
PD) are primarily composed of fibrillary α-synuclein (Spillantini et al., 1998).  Therefore, 
the current results suggest the change in inflammatory property in human A172 astroglial 
cells may be potentiated by the presence of α-synuclein fibrillary polymers.   
The present data is the first report examining the role of extracellular, aggregated 
α-synuclein on human astroglial cells.  Only one other study has explored the effects of 
α-synuclein on CXCL10 protein expression, yet this was studied in mouse mixed glia and 
isolated microglia cultures (Roodveldt et al., 2010).  The same group found CXCL10 
protein levels produced by unstimulated cells and wild-type α-synuclein-alone treated 
cells to be at a low level in both microglia-astroglia mixed culture and the isolated 
microglia culture (Roodveldt et al., 2010).  The low expression of CXCL10 by glial cells 
in α-synuclein treatments is similarly demonstrated in the present data.  On the other 
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hand, several studies reveal α-synuclein’s ability to enhance production of other 
inflammatory factors (Gao et al., 2011; Gu et al., 2010; Reynolds et al., 2008a).  For 
example, α-synuclein significantly increased the levels of MCP-1, MIP-1, and RANTES 
in microglial cells and mixed astroglia-microglia co-culture (Reynolds et al., 2008a; 
Roodveldt et al., 2010).  Klegeris et al. (2006) reported that α-synuclein stimulated 
human astrocytes as well as human astrocytoma cells to up-regulate both IL-6 and 
ICAM-1.  The results, however, were obtained from studies that demonstrated several 
differences compared to the current study, including cell- and species-specific differences 
and α-synuclein conformational differences.  Although previous studies reveal a 
regulation of inflammatory factors by α-synuclein on glial cells, outcomes from the 
present study agree with Roodveldt et al. (2010), which indicate that α-synuclein alone is 
not able to increase the production of CXCL10. 
Results of enhanced glial CXCL10 protein expression by the cytokines in the 
current study are in agreement with other studies (Davis et al., 2007; John et al., 2001; Qi 
et al., 2009).  For instance, IL-1β induced the expression of CXCL10 protein in human 
fetal astrocytes (John et al., 2001).  In a study conducted by the current laboratory, 
published results revealed an enhanced CXCL10 expression by TNFα and IL-1β in 
human A172 astrocytes relative to unstimulated cells (Davis et al., 2007).  Overall, our 
results correlate with others and state that TNFα and IL-1β are capable of stimulating the 
production of CXCL10 in astroglial cells. 
Examining α-synuclein in the presence of either TNFα or IL-1β was found to up-
regulate cytokine-induced CXCL10 expression in A172 cells.  This is the first study to 
examine the effect of α-synuclein in the presence of either cytokine on CXCL10 protein 
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expression in human astroglial cells.  Interestingly, few other reports have examined the 
combination of α-synuclein and inflammatory factor(s) on the alterations of 
cytokines/chemokines (Gao et al., 2011; Klegeris et al., 2006).  For example, Klegeris et 
al. (2006) studied the in vitro expression of IL-6 and ICAM-1 induced by α-synuclein in 
astroglia.  Results revealed that the addition of α-synuclein and IFNγ to human astrocytes 
and astrocytoma cells resulted in an increase in ICAM-1 and IL-6 levels.  Additionally, 
Gao et al. (2011) examined the effects of α-synuclein with the TLR4 ligand 
lipopolysaccharide (LPS) on neuroinflammation in brains of mice.  Specifically, Gao and 
colleagues (2011) detected an up-regulation of multiple inflammatory markers, including 
Iba-1, Mac1, iNOS, and cyclooxygenase-2 (COX-2) in both the SN and striatum of 
transgenic mice overexpressing human A53T mutant α-synuclein. The up-regulation of 
inflammatory markers was relative to LPS-injected wildtype mice and was consistent 
with chronic progressive degeneration of nigrostriatal dopamine pathway.  Examining the 
effects of α-synuclein on glial CXCL10 expression did not increase the expression of the 
chemokine at lower TNFα concentrations in the current study.  The data indicate that 
TNFα at 5 ng/ml may provide a threshold level needed for α-synuclein to have an effect 
on CXCL10 protein expression in A172 cells.  Data with IL-1β-induced CXCL10 
expression also demonstrated a significant up-regulation by α-synuclein at an IL-1β 
concentration of 0.25 ng/ml.  The result may indicate that maximum CXCL10 production 
may be achieved at IL-1β greater than 0.25 ng/ml; therefore, not allowing further 
enhancement of chemokine production by the addition of α-synuclein.  Nonetheless, α-
synuclein co-exposed with TNFα or IL-1β potentiated the enhancement of CXCL10 
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expression in human astroglial cells, demonstrating a potential involvement of α-
synuclein in PD neuroinflammation.   
The consequences of altered CXCL10 expression in dopamine associated 
neuropathology have not been fully elucidated.  Depending on the temporal, regional, and 
magnitude of expression in the brain, CXCL10 may be neuroprotective or neurotoxic.  
CXCL10 can display neuroprotective properties via antimicrobial activities (Cole et al., 
2001).  Neurotoxic behavior of CXCL10 is well documented in neurological diseases 
(Sui et al., 2004; Sui et al., 2006; Tanuma et al., 2006; van Marle et al., 2004).  For 
instance, a study demonstrated neuronal death caused by the supernatant of HIV-1 Nef 
exposed astrocytes was blocked by an antibody to the CXCL10 receptor, CXCR3 (van 
Marle et al., 2004).  Another study revealed that cultured human fetal brain neurons 
treated with CXCL10 activate caspase-3 and ultimately leads to apoptosis (Sui et al., 
2004).  Although chemokines are elevated in the PD brain (Roodveldt et al., 2010), their 
consequences on dopaminergic neurons are yet to be determined in PD.  Therefore, a 
strong support of the neurotoxic effects of CXCL10 exists in other neurodegenerative 
disease, and thus, may have similar outcomes in PD. 
5.2 Alpha-synuclein did not modulate cytokine-stimulated CXCL10 mRNA in 
human A172 cells 
Examining transcriptional regulation by α-synuclein may provide insight into the 
mechanisms of α-synuclein induced CXCL10 protein expression in A172 cells.  The 
enhancement of the levels of CXCL10 mRNA by IL-1β in the current study was similarly 
seen in a study by John et al. (2001).  In this study, a group of researchers detected IL-1β-
induced expression of CXCL10, as well as IL-8 and MCP-1, mRNA in human primary 
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astrocyte cultures (John et al., 2001).  Furthermore, previous study in A172 cells also 
demonstrated the ability of IL-1β to trigger CXCL10 mRNA expression; however, cells 
were also co-exposed with LPS (Davis and Syapin, 2004b).  The time-dependent effect of 
IL-1β on CXCL10 mRNA observed in the present study was also observed by Williams 
et al. (2009), who revealed a similar time-dependent increase of CXCL10 mRNA levels 
after IL-1β treatment in A172 cells (Williams et al., 2009a).  Overall, results revealed in 
the current study confirm previous studies and indicate the capability of IL-1β to induce 
CXCL10 mRNA in A172 cells in a time-dependent manner.  The induction of CXCL10 
mRNA by IL-1β may be due to signaling pathways that activate transcription factors, 
such as NF-κB, that facilitate mRNA production, as seen in previous studies (John et al., 
2001; Yeruva et al., 2008).  
When evaluating the cooperative effects of α-synuclein and IL-1β on CXCL10 
mRNA expression, the lack of change by α-synuclein on IL-1β-induced CXCL10 mRNA 
expression was different compared to the single study that also examined α-synuclein 
effects on astroglial CXCL10 mRNA (Lee et al., 2010b).  Conditioned media from α-
synuclein-expressing human neurons transferred to rat astrocytes resulted in an induction 
of CXCL10, as well as other (CCL2, CCL5, CXCL1, CXCL2), mRNA levels.  The study 
also determined that α-synuclein did not have an effect on astroglial mRNA levels of a 
particular chemokine (CCL6) and down-regulated mRNA levels of other mediators (Lee 
et al., 2010b).  The dissimilarity in results between the current study and Lee et al. may 
be due to species-specific differences.  Furthermore, while human α-synuclein was aged 
in the present study to obtain aggregated conformation,  neuronal cells used by Lee et al. 
(2010) were transfected with adenoviral vector containing human α-synuclein cDNA.  
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The difference in α-synuclein preparation may have different cellular and molecular 
effects in astrocytes.  Overall, the current results suggest that α-synuclein does not 
mediate the induction of IL-1β-induced CXCL10 mRNA expression.  Several 
possibilities could be responsible for this effect by α-synuclein, including structural 
modifications of α-synuclein.  Alpha-synuclein possesses conformational plasticity and 
the structure of this protein depends on its environment (Uversky 2007), implying that α-
synuclein may undergo structural modifications that do not exhibit regulation of the 
CXCL10 mRNA expression.  Furthermore, Jin et al. (2011) recently demonstrated that α-
synuclein mechanistically regulated PKCδ gene expression by negatively inhibiting NF-
κB activity and reducing p300 (transcriptional co-activator) levels.  However, the 
reduction of PKCδ was examined in dopaminergic neurons transfected with α-synuclein.  
Exogenous α-synuclein may portray different effects in astroctes relative to neurons, 
ultimately resulting in a lack of induction of IL-1β-stimulated CXCL10 mRNA, although 
further research is needed.  The enhancement of CXCL10 protein expression observed in 
A172 cells by α-synuclein may therefore potentially be elicited by post-transcriptional 
modifications of α-synuclein.  
 
5.3 Alpha-synuclein induced cytokine-stimulated CXCL10 mRNA stability 
 
Post-transcriptional control of gene expression through mRNA transcript stability 
is important in the regulation of inflammatory genes, particularly of those encoding 
cytokine and chemokines (Sun and Ding, 2006).  CXCL10, in particular, has a transcript 
half-life that is rather short (about 30 minutes) under resting conditions (Shanmugam et 
al., 2006).  In order to examine transcript stability, the addition of de novo transcription 
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inhibitors was studied in culture.  The DNA-dependent RNA synthesis inhibitor 
actinomycin D is a widely used inhibitor in mRNA transcription stability studies (Dhillon 
et al., 2007; Galbis-Martinez et al., 2010; Okamoto et al., 2008; Shanmugam et al., 2006).  
Mechanistically, actinomycin D binds DNA at the transcription initiation complex of 
genes and prevents transcript elongation by RNA polymerase.  Therefore, assessment of 
whether the actinomycin D – DNA binding sequence is present in the CXCL10 DNA 
sequence was made using DNAStar, a program that searches for a specific gene sequence 
within another gene sequence.  The results found the actinomycin D – DNA binding 
sequence is within the human CXCL10 DNA sequence (data not shown); therefore, 
indicating actinomycin D can bind to the specific gene of interest.  The time-dependent 
inhibition of cytokine-induced CXCL10 mRNA transcripts by actinomycin D observed in 
the current study were similarly demonstrated in other studies (Dhillon et al., 2007; 
Galbis-Martinez et al., 2010; Okamoto et al., 2008; Shanmugam et al., 2006).  For 
instance, CXCL10 mRNA transcript levels from IFNγ +/- PDGF (platelet-derived growth 
factor) stimulated monocytes were significantly decreased as early as 20 minutes post-
actinomycin D treatment (Dhillon et al., 2007).  The decrease of CXCL10 mRNA levels 
in the presence of actinomycin D continued to be significant even at the latest time point 
tested, 2 hours.   A similar trend of CXCL10 mRNA transcript inhibition by actinomycin 
D occurred in murine embryonic fibroblasts stimulated with poly(ADP-ribose) 
polymerase-1 (Galbis-Martinez et al., 2010).  Inhibition was present at 1 hour post-
inhibitor exposure and continued for 12 hours.  Therefore, the DNA-dependent RNA 
synthesis inhibitor actinomycin D is capable of blocking synthesis of new CXCL10 
mRNA transcripts in A172 cells as well as other cell types.     
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Next, the effect of α-synuclein was examined on IL-1β-induced CXCL10 mRNA 
stability in A172 astroglial cells using an actinomycin D concentration of 10 µg/ml, 
which is a concentration consistent with that used by others (Gardner et al., 2006; 
Kasahara et al., 1991; Yao et al., 2005).  The reduction of CXCL10 mRNA decay by α-
synuclein relative to IL-1β treatment in the current study indicates that α-synuclein 
facilitates the stability of this CXCL10 mRNA in A172 cells.  However, it remains 
unclear whether the effect by α-synuclein is direct or indirect.  This is the first report on 
the role of α-synuclein on CXCL10 mRNA stability in IL-1β-exposed A172 cells.  
Interestingly, a single study has been reported regarding the role of α-synuclein on 
mRNA stability (Jin et al., 2011).  This recent study by Jin et al. (2011) reported α-
synuclein stably transfected into dopaminergic neurons resulted in protein kinase C-γ 
transcription suppression without any changes in mRNA stability.  The effect by α-
synuclein may be relative to this gene of interest in neuronal cells; however, it does not 
implicate a similar effect on other genes in different cell types.  Furthermore, CXCL10 
transcribed in the cell is expected to be degraded rapidly because of endogenous 
destabilizing mechanisms (Shanmugam et al., 2006).  From the current data, results may 
suggest that α-synuclein may promote CXCL10 mRNA stability by delaying/inhibiting 
its degradation or destabilization.  Certain proteins interact with mRNA transcripts to 
regulate mRNA degradation.  From the list of these proteins (i.e. parp-1, HuR, S100b, 
nucleolin), only nucleolin has been shown to interact with α-synuclein (Jin et al., 2007).  
The apparent role nucleolin plays on stabilizing mRNA involves its participation with the 
5’ and more so 3’ untranslated regions (5’ , 3’-UTR) of mRNA.  Specifically, nucleolin 
binds to the 5’ and 3’ UTRs of specific mRNAs, enhancing both their stability and 
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translational efficiency.  Jin et al. (2007) demonstrated the presence of nucleolin-bound 
α-synuclein through confocal microscopy, western immunoblotting, and 
immunoprecipitation (Jin et al., 2007).  Confocal microscopy further revealed 
localization of nucleolin in both the nucleolus and cytoplasm compartments.  In 
correlation with the current study, three possibilities for the increased mRNA stability by 
α-synuclein may be reasonable.  One, aggregated α-synuclein may lead to a dissociation 
of nucleolin from α-synuclein and ultimately bind CXCL10 mRNA transcripts to 
promote stability.  Secondly, a possibility may be the direct interaction of α-synuclein on 
stability.  Alpha-synuclein, along with the bound nucleolin, may directly bind to the 
CXCL10 mRNA transcripts and enhance transcript stability.  Jin et al. (2007) also 
demonstrated a significant reduction in nucleolin from α-synuclein in rat dopaminergic 
mesencephalic neuronal cell cultures after rotenone (a pesticide thought to be involved in 
PD) exposure.  The nucleolin reduction may support the first possibility of dissociated 
nucleolin, though this may be a specific cause of rotenone and may differ with the current 
model.  Third, α-synuclein may yet induce other stabilizing RNA-binding proteins or 
inhibit de-stabilizing RNA-binding proteins directly or indirectly, ultimately mediating 
CXCL10 mRNA stability.   
5.4 Alpha-synuclein modifications on NF-κB signaling in cytokine-stimulated 
human A172 astroglial cells  
The NF-κB signaling pathway is responsible for the induction of several 
inflammatory factors.  The activation of NF-κB is examined by the translocation of NF-
κB p65/p50 from the cytoplasm into the nucleus.  In the current study, the significant up-
regulation of the levels of active nuclear p65 protein by cytokine-alone correlates with 
other published data (Davis et al., 2007; Nadjar et al., 2003; Qi et al., 2009).  For 
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instance, the exposure of A172 cells to TNFα resulted in an increase in nuclear p65 
proteins (Davis et al., 2007).  Other studies have demonstrated the ability of α-synuclein-
alone to enhance NF-κB activation (Alberio et al., 2010; Klegeris et al., 2006; Reynolds 
et al., 2008b; Togo et al., 2001; Yuan et al., 2008).  For instance, Reynolds et al. (2008) 
demonstrated an enhancement of p65 and p50 levels in the nucleus of microglial cells in 
the presence of aggregated and nitrated α-synuclein.  The results by Reynold et al. (2008) 
were a measurement of total protein as oppose to active protein in the nucleus.  
Furthermore, the use of a higher concentration of α-synuclein as well as different cell-
specific and α-synuclein preparation may have led to differences in results between the 
previous study and the current results.  Klegeris et al. (2006) detected the activation of 
ERK1/2 and JNK MAPKs by non-aggregated α-synuclein in microglial cells, thus 
illustrating the involvement of other signaling pathways in glial cells by α-synuclein.  
Although several differences exist between Klegeris et al. and the present study (α-
synuclein preparation and cell type), the outcomes do not eliminate the involvement of α-
synuclein in NF-κB signaling due to the possible interactions between different signaling 
pathways.  Nonetheless, the present results are the first report on α-synuclein modulation 
of levels of p65/p50 in A172 astroglial cells.    
The lack of modulation observed by α-synuclein on IL-1β-induced phospho-IκBα 
and p65 levels was contrary to the observed enhancement of TNFα-induced p65 levels by 
α-synuclein.  The results indicate a role of α-synuclein on NF-κB activation in the 
presence of TNFα.  Although these results in the current study are the first to demonstrate 
α-synuclein’s role on TNFα- and IL-1β-induced NF-κB activity, several lines of evidence 
support α-synuclein’s involvement in inflammatory-induced NF-κB activity (Alberio et 
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al., 2010; Lee et al., 2010a; Prabhakaran et al., 2011; Wilms et al., 2009).  For example, 
Parbhakaran et al. (2011) evaluated the mechanism involved in manganese-induced 
neurotoxicity in the presence of α-synuclein.  Human α-synuclein enhanced manganese-
induced neurotoxic susceptibility by activating the NF-κB signaling pathway, specifically 
NF-κB nuclear translocation.  This enhancement was further blocked by an NF-κB 
inhibitor (SN50).  The reason for the different results between TNFα and IL-1β-induced 
NF-κB activity by α-synuclein in the current study remains unclear.  One explanation for 
the difference may be α-synuclein’s ability to facilitate actions of the TNF receptor 
and/or the receptor’s adaptor proteins, ultimately enhancing active p65 levels in the 
nucleus.  Other explanations may be an activation of a different signaling pathway by α-
synuclein in IL-1β-stimulated astrocytes.  This latter explanation is in agreement with 
current results that demonstrate a lack of regulation by α-synuclein on the 
phosphorylation of IκBα, as well as with previous reports where α-synuclein activates 
other signaling pathways beside NF-κB, such as MAP kinase (Klegeris et al., 2008; 
Wilms et al., 2009).  Astrocytes co-exposed to α-synuclein and IFNγ resulted in an 
enhanced activation of MAP kinase pathways p38, ERK1/2, and JNK via protein 
phosphorylation (Klegeris et al., 2008).  Another explanation for the difference between 
α-synuclein’s effect on TNF- and IL-1β-induced NF-κB activation may be due to 
cytokine concentrations used.  The concentration of TNFα used in the current study may 
have been at a threshold level that allows α-synuclein to facilitate NF-κB activation, 
whereas IL-1β concentrations were not and therefore did not allow modulation by α-
synuclein.    
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Interestingly, the lack of modulation on IL-1β-induced NF-κB by α-synuclein does 
not mirror the enhanced IL-1β-induced CXCL10 protein expression.  In this case, α-
synuclein may induce other signaling pathways in astrocytes that will mirror the 
induction of CXCL10 protein expression. 
5.5 Alpha-synuclein did not alter cell viability 
A number of in vivo and in vitro studies have reported the toxic actions of α-
synuclein on oligodendroglial and neuronal cells (Bisaglia et al., 2010; Gao et al., 2011; 
Gu et al., 2010; Kragh et al., 2009; Zhang et al., 2005).  For instance, Kragh et al. (2009) 
observations revealed a cellular degeneration and apoptosis in oligodendrocytes induced 
by α-synuclein.  Additionally, aggregated α-synuclein at concentrations similar to the 
concentrations used in the current study resulted in dopaminergic neurotoxicity in rat 
primary mesencephalic neuronal cultures (Zhang et al., 2005).  Neurotoxicity was even 
displayed in in vivo studies where α-synuclein resulted in significant neuronal loss in the 
midbrain region of mice models (Gao et al., 2011; Gu et al., 2010).  Although these 
studies on neuronal cells illustrate a neurotoxic role of α-synuclein, A172 astroglial cells 
appear to be less susceptible to α-synuclein-induced cytotoxicity.  This observation was 
the first report on α-synuclein’s effect on A172 viability.  Although concentrations of α-
synuclein used in the current study did not impact astroglial viability, higher 
concentrations of this protein may ultimately result in a significant increase in cellular 
toxicity.  Measures of cell viability, such as trypan blue and lactate dehydrogenase 
release assays, may give different results and therefore demonstrate fewer viable cells.  
Furthermore, astrocytes produce protective factors that result in an autocrine or paracrine 
effect, eventually demonstrating less susceptibility to toxic compounds.  For instance, α-
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synuclein is shown to induce oxidative stress in a number of cells, including astrocytes 
(Farooqui and Farooqui, 2011; McGeer and McGeer, 2008).  Astrocytes, which produce 
the anti-oxidant glutathione under stressful conditions, may relieve the oxidative stress 
produced within the cell or in adjacent cells (Fuller 2009).  Interestingly, the ability of α-
synuclein to induce glutathione in response to heightened oxidative stress has been 
demonstrated (Hsu 2000).  The possible explanations listed could result in less 
susceptibility of astrocytic data in α-synuclein pathology, yet further examination is 
needed.   
5.6 Alpha-synuclein did not modulate cytokine-induced CXCL10 protein 
expression in Normal Human Astrocytes  
In addition to examining the effects of α-synuclein on CXCL10 protein 
expression in human A172 astrocytoma cells, we concurrently examined these effects in 
normal human astrocytes (NHA).  While IL-1β-stimulated CXCL10 levels were not 
affected by the current α-synuclein concentrations, other α-synuclein and IL-1β 
concentrations may lead to enhanced chemokine levels in NHA cells.  For instance, 
CXCL10 protein levels may be modulated by higher α-synuclein and IL-1β 
concentrations than used in the current study.  To date, only two groups of researchers 
have examined cytoactive molecules in α-synuclein-exposed primary astroglial cells.  
One group demonstrated a dose-dependent up-regulation of matrix metalloproteinase-9 
by α-synuclein while observing a decrease of activity of the tissue plasminogen activator 
(Joo et al., 2010), whereas the other group demonstrated an increase in ICAM-1 and IL-6 
(Klegeris et al., 2006).  Therefore, although α-synuclein is shown to regulate certain 
molecules at the same concentrations that were used in the present study, this protein did 
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not result in a significant modification of the CXCL10 protein levels in the NHA cell 
line.  Possible explanations for the lack of regulation by α-synuclein on NHA may be due 
to concentrations used or resistance to current α-synuclein configuration.  Relative to 
NHA, A172 cells may be more sensitive to the effects of α-synuclein. 
5.7 Alpha-synuclein elevated nitrite production in cytokine-stimulated human 
A172 astroglial cells 
The inducible NOS isoform has received considerable attention due to the 
enzyme’s ability to produce cytotoxic levels of NO.  The up-regulation of iNOS, which is 
measured via nitrite accumulation, by a mixture of cytokines is supported by Davis et al. 
(2007), where an increase in iNOS activation is evident by astroglial NOS2 mRNA 
enhancement by the same cytokine mixture used in the current study.  This study is the 
first to show α-synuclein mediated increases in cytokine-induced iNOS expression in 
human astroglial cells.  Similarly, Gao et al. (2008) observed a nitrite accumulation and 
an increase in iNOS levels in microglial cells in the presence of α-synuclein with LPS 
relative to unstimulated cells.  The study also revealed that the abatement of NO from α-
synuclein and LPS co-exposed microglial cells provided significant neuroprotection in 
neuron-glia cultures.  Another study revealed similar results, with an increase in 
microglial iNOS expression, which ultimately led to dopaminergic neuronal degeneration 
(Stefanova et al., 2007).  The mechanism of α-synuclein mediated increase in iNOS 
expression is unclear, but may be a consequence of potentiating the activation of 
signaling pathways.  For instance, an inhibition in glial iNOS expression in an in vitro 
MPTP model was mirrored with an inhibition of IκBα induction and p65 translocation 
into the nucleus, suggesting a role for NF-κB involvement in glial iNOS induction 
113 
 
(Dehmer et al., 2004).  On the other hand, Waak and colleagues (2009) demonstrated an 
involvement of the p38 MAP kinase in the production of NO in DJ-1 mutated astrocytes 
(Waak et al., 2009).  The results demonstrate the potential involvement of inflammatory 
signaling pathways that mediate the enhanced nitrite production by astrocytes. 
The consequences of altered nitrite production in PD-associated neuropathology 
have not been fully elucidated.  Depending on the temporal, regional, and magnitude of 
expression in the brain, iNOS expression may be neuroprotective or neurotoxic.  At low 
levels, NO functions beneficially as both an antitumor and antimicrobial agent, whereas 
high levels of NO can be cytotoxic (Kroncke et al., 1997; Lipton, 1999; Liu and Stamler, 
1999).  In PD studies, an increase in iNOS expression and nitrite production results in 
neuronal death (Dehmer et al., 2004; Stefanova et al., 2007).  Findings demonstrated an 
up-regulation of glial iNOS expression by α-synuclein and MPTP correlated with 
dopaminergic neuronal loss, with iNOS suppression protecting dopaminergic SNpc 
neurons (Dehmer et al., 2004; Stefanova et al., 2007).  Although further examination is 
needed to elucidate the effect of α-synuclein-induced nitrite production in astrocytes, the 
current data suggest that NO released by astroglial cells may be a mediator that links 
neuroinflammation and aggregated α-synuclein in PD neurodegeneration.    
 
 
 
 
 
 
 
114 
 
Part II 
 
 
Neuromelanin and oxidized dopamine modulation on inflammatory signaling  
in TNFα-stimulated human A172 astroglial cells 
 
 
5.8 Neuromelanin and oxDA inhibit CXCL10 protein expression in A172 
astroglial cells 
 
Several studies have demonstrated that chemokines and chemokine receptors are 
associated with dopaminergic neurodegeneration (Rentzos et al., 2007; Shimoji et al., 
2009) as evidenced by their increased expression.  The consequences of altered 
chemokine (i.e, CXCL10) expression in dopaminergic associated neuropathology have 
not been fully elucidated.  Modulation of astroglial CXCL10 expression by NM, could 
potentially have important implications in neuropathologies associated with 
dopaminergic neurons. 
Our results indicate TNFα-induced CXCL10 expression in A172 astroglia is 
markedly decreased by oxDA and NM.  This down-regulation of CXCL10 was not a 
consequence of altered cell viability by oxDA and NM in A172 cells; although, astroglial 
toxicity was seen when exposed to oxDA at the highest concentration used.  There are no 
other reports in the literature describing the specific effects of oxDA or NM on CXCL10 
expression in human astroglia.  Although nothing is known about the effects of oxDA or 
NM on CXCL10 levels in PD, the reduction in the level of CXCL10 presented in our 
study provides new insights to the effects of oxDA or NM on proinflammatory-induced 
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CXCL10 expression in astroglia.  Yet, it could be speculated that astroglial-derived 
CXCL10 plays a neuroprotective role in PD and therefore, oxDA or NM in excess could 
restrict this process, but further investigation is necessary.  Another consideration of the 
effects of oxDA and NM is that astroglial CXCL10 expression may promote 
neurotoxicity and oxDA/NM reduction of the chemokine reflects a potential 
neuroprotective effect of NM.  The idea that NM is neuroprotective is consistent with 
previous reports (Zecca et al., 2006).  In fact, in physiological conditions the NM 
synthesis is a protective process which removes excess cytosolic DA which would 
otherwise cause neurotoxicity (Sulzer et al., 2000).  Moreover, NM is a strong chelator of 
metals which blocks reactive toxic metals and forms stable complexes (Zecca et al., 
2003).  Once these actions of NM have been overwhelmed, the pathogenic actions of NM 
destroy NM-containing neurons, resulting in leakage of NM granules into the 
extracellular environment, and eventual disease aggravation. 
5.9 Neuromelanin and oxDA reduce proinflammatory-induced active NF-κB 
signaling proteins in A172 astroglial cells 
Activation of the transcription factor, NF-κB, is associated with dopaminergic 
associated neuropathology.  For instance, within the ventral midbrain of PD patients, NF-
κB p65 levels are elevated in microglia and astrocytes as compared to age-matched 
controls (Ghosh et al., 2009).  Similarly, in a mouse model of PD, MPTP significantly 
induced NF-κB activation in astrocytes of the substantia nigra (Aoki et al., 2009).  
Furthermore, a previous study demonstrated that NF-κB activation is instrumental in 
TNFα-induced CXCL10 expression in human astroglial cells through the use of specific 
NF-κB inhibitors (Davis et al., 2007).  In the current study, both oxDA and NM reduced 
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TNFα-induced NF-кB activation by decreasing levels of active nuclear p65 protein.  The 
mechanism by which NM reduces NF-κB activation is unclear; however, several 
possibilities exist.  Neuromelanin may influence the inhibition of IκBα phosphorylation 
or the exposure of nuclear translocation sequence on NF-κB proteins, thus reducing the 
amount of NF-κB proteins translocating into the nucleus.  Neuromelanin may enter the 
nucleus, ultimately reducing the levels of active NF-κB proteins detected by binding to 
NF-κB proteins or facilitating the export of the proteins out of the nucleus.   Additionally, 
the current results suggest that NM inhibits TNFα-induced CXCL10 expression in human 
astroglial cells, in part, through an NF-κB p65 dependent mechanism.  The importance of 
NM mediated inhibition of NF-κB activation likely extends beyond just inhibition of 
CXCL10 expression.  That is, the expression of many inflammatory molecules in 
astrocytes is transcriptionally regulated by NF-κB.  Therefore, NM may inhibit 
transcription of multiple inflammatory molecules in astroglia.  In contrast, in rat 
microglia, NM induces inflammatory signaling including NF-κB activation, and 
expression of inducible nitric oxide synthase and TNFα (Wilms et al., 2003; Zhang et al., 
2011).  Together, these findings suggest that NM modulation of inflammatory signaling 
may differ among glial cell types.  However, this is the first report to assess the specific 
effects of oxDA or NM on astroglial NF-кB activation.  This decline of NF-κB activation 
by oxDA or NM was parallel to a decline in both CXCL10 protein levels, proposing a 
possible correlation. 
5.10 Oxidized dopamine- and neuromelanin-induced cytotoxicity in human 
neuronal and/or glial cells.  
Previous studies suggest that NM-induced neurotoxicity is promoted by NM 
release from damaged dopaminergic neurons resulting in microglial activation and 
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production of neurotoxic molecules which further damage dopaminergic neurons (Wilms 
et al., 2003; Zecca et al., 2003; Zecca et al., 2006; Zecca et al., 2008; Zucca et al., 2004).  
In the current study, chemokine expression was not regulated by oxDA and NM alone; 
consequently, the effects of oxDA and NM on neuronal and glial viability were not of 
interest.  In the presence of cytokines, a chronic exposure of SK-N-SH neuronal cells to 
oxDA results in a rapid reduction of viability in cells.  Furthermore, chronic NM 
exposure dose-dependently reduces viability in TNFα-exposed SK-N-SH neuronal 
cultures.  The oxDA- and NM-induced cytotoxicity in human neuronal cells may partly 
explain the neuronal toxicity observed in PD.  For instance, others have shown that 
dopamine triggered apoptotic pathways in striatal neurons in in vitro and in vivo 
(McLaughlin et al., 1998) and induced oxidative stress and selective neurodegeneration 
in cell cultures (Stokes et al., 2000).  Moreover, an oxidative-deamination metabolite of 
dopamine, 3,4-Dihydroxyphenylacetaldehyde (DOPAL) was responsible for 
neurodegeneration of PC12 cell cultures, possibly by inhibition of mitochondria complex 
I dysfunction (Lamensdorf et al., 2000).   
Although previous works illustrate neurodegeneration by NM to be mediated by 
microglial cells (Rao et al., 2006; Wilms et al., 2003; Zecca et al., 2008), the current 
results show that NM exposed to dopaminergic SK-N-SH neuronal cells induces damage.  
In support of the NM-induced neurodegeneration, NM is shown to cause abnormal 
protein accumulation by inhibiting the proteolytic activities of the 26S proteasome and 
eventually lead to neuronal death in PD (Lopez Salon et al., 2003; Rao et al., 2006; 
Shamoto-Nagai et al., 2004; Song and Jung, 2004), or may selectively induce apoptosis 
in dopaminergic SH-SY5Y neuronal cells via mitochondrial deglutathionylation (Naoi et 
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al., 2008).  In another study, NM (1-100 µg/ml) dose-dependently inhibited viability in 
primary cultures of mesencephalic dopaminergic neuronal cells (Nguyen et al., 2002).  
However, in this study, a synthetic melanin was employed and this has structure/behavior 
differences from human NM (Zecca et al., 2000).  Compared to SK-N-SH neuronal cells, 
CHME-5 microglia and A172 astroglia are far less susceptible to oxDA- and NM-
induced cytotoxicity.  While previous studies concerning NM effects on microglia 
morphology and activation were performed with primary rat cultures (Wilms et al., 
2003), this is the first report describing the effects of oxDA and NM on human microglial 
and astroglial viability.  These findings are consistent with the concept that glial cells in 
the brain can survive and may even proliferate under conditions where neuronal cells 
degenerate (Hirsch et al., 2003; Wilms et al., 2003).  Cellular cultures of primary 
neuronal and glia from PD in vivo rats cause mitigation of the neurodegenerative effects 
of oxDA and NM (Depboylu et al., 2007), in part through up-regulation of anti-
inflammatory molecules or abatement of pro-inflammatory molecules and ROS 
production.  The detrimental role of these activated glial cells may be associated with an 
up-regulation of proinflammatory molecules, including NO, cytokines and chemokines.  
In fact, several studies have demonstrated that dopamine and NM are inflammation-
inducing molecules (Armentero et al., 2006; Hunot and Hirsch, 2003; Wilms et al., 2003; 
Zecca et al., 2006; Zecca et al., 2008).  Therefore, while reactive microglia and reactive 
astrocytes are prominent in affected areas of the SN, neurodegeneration could occur due 
to a greater sensitivity of dopaminergic neurons to oxidative stress compared with glial 
cell sensitivity (Iwata-Ichikawa et al., 1999; McGeer and McGeer, 2008).  This 
vulnerability to oxidative stress in dopaminergic neurons is caused by numerous factors.  
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Some examples include high amounts of dopamine molecules undergoing oxidation, low 
antioxidant protection due to low glutathione, high levels of lipid peroxide and iron 
deposition, and saturation of NM leading to increase levels of ROS (Double et al., 2002; 
Zecca et al., 2006; Zecca et al., 2008).   
5.11 Oxidized dopamine and neuromelanin enhances proinflammatory-induced 
nitrite production in human astroglial cells 
As mentioned before, numerous studies have demonstrated the involvement of 
iNOS in neuropathology associated with Parkinson disease (Aquilano et al., 2008; 
Arimoto and Bing, 2003; Hunot et al., 1996; Iravani et al., 2002; Marchetti et al., 2005).  
A cocktail of three cytokines (TNFα, IL-1β, and IFNγ) is required to induce iNOS 
expression in A172 cells (Davis and Syapin, 2004a; Davis and Syapin, 2004b).  From the 
current results, the induction of iNOS by the cytokine mixture was not affected by oxDA 
or NM.  This may reflect an inability of oxDA or NM to modulate maximal induction of 
iNOS that occurs in the presence of this cytokine mixture.  TNFα alone is not sufficient 
to induce iNOS in A172 cells.  However, suboptimal iNOS induction by TNFα alone is 
potentiated by oxDA and NM.  A possible mechanism for NM’s effect on TNFα-induced 
iNOS expression is activation of the signaling pathway.  A number of studies have found 
the NF-κB pathway to be involved in iNOS expression (Nomura, 2001; Wang et al., 
1999), however results from current study revealed an inhibition of NF-κB activation by 
NM.  Other signaling pathways, such as the MAP kinase pathways, are also involved in 
the induction of iNOS expression (Kaminska, 2005) and the p38 MAP kinase, in 
particular, has been observed to be activated by human NM in glial cells (Wilms et al., 
2003).  Therefore, the induction of nitrite production by NM in TNFα-exposed astrocytes 
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may be due to activation of the p38 MAP kinase signaling pathway by NM in these cells, 
however, further examination is needed.  Overall, the current study is the first to assess 
the specific effects of oxDA or NM on astroglial iNOS induction.  Inducible NOS is 
upregulated in PD (Boka et al., 1994; Hirsch et al., 2003; Hunot et al., 1999; Knott et al., 
2000) and; therefore, current results are in agreement with other glial studies (Rao et al., 
2006; Wilms et al., 2003; Zecca et al., 2006; Zhang et al., 2011).  For instance, 
extracellular NM was found to induce microglial production of NO (Wilms et al., 2003; 
Zecca et al., 2006; Zhang et al., 2011) as well as other inflammatory mediators.  
Nonetheless, this study provides novel insights into the effects of NM on inflammatory 
signaling in human astroglial cells. Depending on the temporal, regional, and magnitude 
of expression, astroglial release of NO may lead to a neuroprotective or neurotoxic effect.  
Although NO may be neuroprotective under certain conditions in the demylinating 
disease MS (Fenyk-Melody et al., 1998), PD studies demonstrate a more neurotoxic role 
of NO (Broom et al., 2011; Kim et al., 2010; Liberatore et al., 1999; Wilms et al., 2003).  
Consequently, a support of neurotoxic NO in PD may portray a significant effect on 
neurodegeneration by NM.  Further analysis of the effects of NM on astroglial NO 
production may lead to an improved understanding of the roles and mechanisms of NM 
in PD.   
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CHAPTER VI 
 
 
SUMMARY 
 
This dissertation represents a two-hit model study that is designed to mimic the 
interactions between PD-associated proteins and inflammation in order to examine 
inflammatory signaling in human astroglial cells.  This study was an investigation on the 
effects of two PD-associated molecules, α-synuclein and NM, on the modulation of 
proinflammatory signaling in human astroglial cells.  Specifically, the objectives that 
were examined in the study were that (1) NM decresed while-synuclein increased 
cytokine-induced CXCL10 and iNOS expression and (2) both PD-associated proteins 
increased NF-κB activation in A172 astroglial cells. 
The examination of inflammatory chemokine expression by α-synuclein agreed 
with a previous study that CXCL10 was up-regulated in PD model compared to healthy 
controls.  Alpha-synuclein induced the expression of CXCL10 in both IL-1β- and TNFα-
stimulated astroglial cells, however, this enhancement by α-synuclein was not 
demonstrated for the mRNA.  Examining post-transcriptional regulation by α-synuclein 
on cytokine-induced CXCL10 mRNA revealed the ability of α-synuclein to mediate an 
increase in mRNA stability relative to cytokine-alone treatments.  This regulation by α-
synuclein may be, in part, the mechanism responsible for the increase in CXCL10 protein
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expression by α-synuclein.  The NF-κB signaling pathway was not activated by α-
synuclein under similar treatments that induced CXCL10 expression.  However, this 
pathway was activated in the presence of other α-synuclein concentrations in TNFα-
stimulated cells, which may suggest the expression of other inflammatory mediators 
besides CXCL10.  An increase in astroglial nitrite accumulation was also observed in the 
presence of α-synuclein, further supporting the inflammation-mediated effects by α-
synuclein. 
 Investigation of role of NM on astroglial chemokine expression revealed a down-
regulation of CXCL10 protein expression.  This decrease in protein expression was 
mirrored with a reduction in NF-κB activation, suggesting a possible mechanism 
responsible for decrease of CXCL10 protein.  On the other hand, NM enhanced cytokine-
induced nitrite accumulation in the presence of astrocytes; however, further studies need 
to be conducted to understand the mechanism.   
Indeed, aggregated α-synuclein and NM modulate astroglial CXCL10 chemokine 
production and iNOS induction.  The changes in inflammatory chemokines and enzymes 
by α-synuclein and NM support a relation between inflammatory-mediated α-
synuclein/NM alterations on astroglial cells.  Although detailed mechanisms remain to be 
defined, these observations suggest a novel mechanism by which PD may progress.  
Together, these results suggest the pathogenic actions of NM and α-synuclein extend to 
the extracellular space and neighboring cells.  Neuromelanin and α-synuclein proteins 
released from neurons may be important mediators of astroglial inflammatory responses 
in PD.  Therefore, the consequences of α-synuclein and NM on astrocytes may cause a 
vicious self-propelling cycle that allows chronic neuroinflammation to persist long after 
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initiation.  The effects of α-synuclein and NM observed in the present study provide 
novel information that may be useful in manipulating ongoing astroglial inflammatory 
responses.  The use of anti-inflammatory drugs may therefore be beneficial and provide 
at least partial relief from neuroinflammation observed in PD. 
In summary, these studies provide an initial understanding on the effects of PD-
associated molecules and inflammation on human brain cells.   Further increasing our 
knowledge of α-synuclein and NM mediated effects may provide new insights into the 
mechanism of disease progression and identify molecular targets for diagnosis and 
therapeutic intervention in PD. 
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Alpha-Synuclein Neuromelanin 
+TNFα@ 
+ α-syn 
(11nM) 
+(TNFα$+IL-
1β*+IFNγ) 
+ α-syn 
(300nM) 
+IL-1β# 
+ α-syn (33nM) 
+TNFα@ 
+ NM (15µg/ml) 
+TNFα@ 
+NM (0.2-5µg/ml) 
R
es
u
lts
 
 CXCL10 
protein 
expression 
 iNOS 
expression 
 CXCL10 
protein 
expression 
 CXCL10 
protein 
expression 
 iNOS 
expression 
No effect 
was 
observed on 
NF-κB 
signaling 
 
No effect was 
observed on 
NF-κB 
signaling and 
CXCL10 
mRNA 
expression, yet 
↑ in CXCL10 
mRNA 
stability 
Lower protein 
may be 
mediated in 
part by ↓ NF-
κB signaling 
 
IFNγ (100 ng/ml) 
@
 TNFα (5 ng/ml) 
$ TNFα (30 ng/ml) 
* IL-1β (5 ng/ml) 
# IL-1β (0.25 ng/ml) 
 
Table IX  Overall summary.  A172 cells exposed to α-synuclein resulted in various outcomes, 
depending on α-synuclein and cytokine concentration.  At the highest concentration examined, 
300 nM α-synuclein and the cytokine mixture enhanced the expression of astroglial iNOS.  At 
lower α-synuclein concentrations, CXCL10 protein expression was induced and may be mediated 
by an increase in mRNA stability in IL-1β-stimulated cells.  On the other hand, neuromelanin 
(NM) decreased CXCL10 expression with a reduction of NF-κB signaling in TNFα-stimulated 
astroglial cell.  Lower concentrations of NM resulted in an increase in iNOS expression in TNFα-
stimulated cells.     
 
Future studies on astrocytes would be conducted to elucidate the effects of α-
synuclein and NM on :  (1) TNFα-stimulated CXCL10 mRNA expression and NF-κB 
activation, (2) TNFα + IL-1β-induced CXCL10 expression, (3) iNOS mRNA expression 
and NF-κB activation (promoter studies), (4) endocytosis of α-synuclein and NM, (5) 
intracellular CXCL10 protein levels, (6) modulation of other chemokines and 
125 
 
ROS, (7) other various signaling pathways using specific inhibitors, and (8) 
neuronal degeneration via astroglial by-products, with degeneration blockage by 
natural or synthetic compounds.  
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Scope and Method of Study:  
The scope of this dissertation was to study the effects of two Parkinson’s disease 
associated molecules, neuromelanin and α-synuclein, on inflammatory signaling and 
expression in A172 astroglial cells in vitro.  Real-time PCR and ELISA were used to 
measure changes in CXCL10 mRNA and protein expression, respectively, and the Griess 
reagent was used to measure nitrite accumulation as an index of iNOS expression.  NF-
κB activation was examined using ELISA-based transcription factor assays. 
 
Findings and Conclusions:   
 The findings from the current study concluded a cytokine-dependent regulation of 
astroglial CXCL10 and iNOS expression by α-synuclein and neuromelanin.  Alpha-
synuclein induced the expression of CXCL10 in both IL-1β- and TNFα-stimulated 
astroglial cells, however, this enhancement by α-synuclein was not demonstrated for the 
mRNA.  Studies revealed the ability of α-synuclein to mediate an increase in mRNA 
stability, which may be, in part, the mechanism responsible for the increase in CXCL10 
protein expression.  The NF-κB signaling pathway was not activated by α-synuclein 
under similar treatments that induced CXCL10 expression yet was activated in the 
presence of other α-synuclein concentrations, suggesting the expression of other 
inflammatory mediators besides CXCL10 may be modulated by α-synuclein.  Alpha-
synuclein also increased astroglial iNOS expression, further supporting the inflammation-
mediated effects by α-synuclein. 
 Investigation of role of NM on astroglial chemokine expression revealed a down-
regulation of CXCL10 protein expression with a reduction in NF-κB activation, 
suggesting a possible mechanism responsible for decrease in CXCL10 protein.  NM 
enhanced cytokine-induced iNOS expression in the presence of astrocytes; however, 
further studies need to be conducted to understand the mechanism.  
 Overall, the findings provide an initial understanding of the effects of PD-
associated molecules and inflammation on human brain cells.  The regulation of 
astroglial-derived inflammatory mediators by extracellular α-synuclein and neuromelanin 
may play a role in PD-associated neuroinflammation.  The observations provide novel 
information that may be useful in identifying molecular targets for therapeutic 
intervention in PD. 
